Document:

Exhibit 10.1 

 

AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN

 

SECTION 1. PURPOSE 

 

The purpose of the ICZOOM GROUP INC. Amended and Restated 2015
Equity Incentive Plan is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent
contractors of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company
and to align their interests and efforts to the long-term interests of the Company’s Shareholders. The original version of this
Plan (the “Prior Plan”) initially became effective upon its approval by the Company’s Shareholders on October 5,
2015 (the “Initial Effective Date”). This Plan has been approved by the Board and shall become effective upon approval by
the Shareholders of the Company on Oct. 26, 2020 (the “Effective Date”) and replaces the Prior Plan in its entirety. Awards
outstanding under the Prior Plan as of the Effective Date remained outstanding in accordance with their terms.

 

SECTION 2. DEFINITIONS 

 

Certain capitalized terms used in the Plan have the meanings set forth
in Appendix A.

 

SECTION 3. ADMINISTRATION 

 

	3.1	Administration of the Plan 

 

The Plan shall be administered by the Board. All references in the
Plan to the “Plan Administrator” shall be, as applicable, to the Board or any committee to whom the Board has
delegated authority to administer the Plan.

 

	3.2	Administration and Interpretation by Plan Administrator 

 

(a) Except for the terms and conditions explicitly set forth in the
Plan and to the extent permitted by applicable law, the Plan Administrator shall have full power and exclusive authority, subject to such
orders or resolutions not inconsistent with the provisions of the Plan as may from time to time be adopted by the Board or a committee
composed of members of the Board, to (i) select the Eligible Persons to whom Awards may from time to time be granted under the Plan;
(ii) determine the type or types of Award to be granted to each Participant under the Plan; (iii) determine the number of Class A
Ordinary Shares to be covered by each Award granted under the Plan; (iv) determine the terms and conditions of any Award granted
under the Plan; (v) approve the forms of notice or agreement for use under the Plan; (vi) determine whether, to what extent
and under what circumstances Awards may be settled in cash, Class A Ordinary Shares or other property or canceled or suspended; (vii) interpret
and administer the Plan and any instrument evidencing an Award, notice or agreement executed or entered into under the Plan; (viii) establish
such rules and regulations as it shall deem appropriate for the proper administration of the Plan; (ix) delegate ministerial duties
to such of the Company’s employees as it so determines; and (x) make any other determination and take any other action that
the Plan Administrator deems necessary or desirable for administration of the Plan.

 

     

     

    

 

(b) The effect on the vesting of an Award
of a Company-approved leave of absence or a Participant’s reduction in hours of employment or service shall be determined by the
Company’s chief human resources officer or other person performing that function or, with respect to directors or executive officers,
by the Board, whose determination shall be final.

 

(c) Decisions of the Plan Administrator shall
be final, conclusive and binding on all persons, including the Company, any Participant, any Shareholder and any Eligible Person. A majority
of the members of the Plan Administrator may determine its actions.

 

SECTION 4. SHARES SUBJECT TO THE PLAN 

 

	4.1	Authorized Number of Shares 

 

Subject to adjustment from time to time as provided in Section 14.1,
a maximum of 12,500,000 Class A Ordinary Shares shall be available for issuance under the Plan. Shares issued under the Plan shall
be drawn from authorized and unissued shares.

 

	4.2	Share Usage 

 

(a) Class A Ordinary Shares covered by an Award shall not be counted
as used unless and until they are actually issued and delivered to a Participant or a Participant’s representative. If any Award
lapses, expires, terminates or is canceled prior to the issuance of shares there under or if Class A Ordinary Shares are issued under
the Plan to a Participant and thereafter are forfeited to or otherwise repurchased by the Company, the shares subject to such Awards and
the forfeited or repurchased shares shall again be available for issuance under the Plan. Any Class A Ordinary Shares (i) tendered
by a Participant or retained by the Company as full or partial payment to the Company for the purchase price of an Award or to satisfy
tax withholding obligations in connection with an Award, or (ii) covered by an Award that is settled in cash or in a manner such
that some or all of the shares covered by the Award are not issued, shall be available for Awards under the Plan. The number of Class A
Ordinary Shares available for issuance under the Plan shall not be reduced to reflect any dividends or dividend equivalents that are reinvested
into additional Class A Ordinary Shares or credited as additional Class A Ordinary Shares subject or paid with respect to an
Award.

 

(b) The Plan Administrator shall also, without
limitation, have the authority to grant Awards as an alternative to or as the form of payment for grants or rights earned or due under
other compensation plans or arrangements of the Company.

 

(c) Notwithstanding any other provision of the Plan to the contrary,
the Plan Administrator may grant Substitute Awards under the Plan. In the event that a written agreement between the Company and an Acquired
Entity pursuant to which a merger or consolidation is completed is approved by the Board and that agreement sets forth the terms and conditions
of the substitution for or assumption of outstanding awards of the Acquired Entity, those terms and conditions shall be deemed to be the
action of the Plan Administrator without any further action by the Plan Administrator, and the persons holding such awards shall be deemed
to be Participants.

 

    2

     

    

 

(d) Notwithstanding any other provisions in this Section 4.2 to
the contrary, the maximum number of shares that may be issued upon the exercise of Incentive Share Options shall equal the aggregate share
number stated in Section 4.1, subject to adjustment as provided in Section 14.1.

 

SECTION 5. ELIGIBILITY 

 

An Award may be granted to any employee, officer or director of the
Company or a Related Company whom the Plan Administrator from time to time selects. An Award may also be granted to any consultant, agent,
advisor or independent contractor for bona fide services rendered to the Company or any Related Company that (a) are not in connection
with the offer and sale of the Company’s securities in a capital-raising transaction and (b) do not directly or indirectly
promote or maintain a market for the Company’s securities.

 

SECTION 6. AWARDS 

 

	6.1	Form, Grant and Settlement of Awards 

 

The Plan Administrator shall have the authority, in its sole discretion,
to determine the type or types of Awards to be granted under the Plan. Such Awards may be granted either alone or in addition to or in
tandem with any other type of Award. Any Award settlement may be subject to such conditions, restrictions and contingencies as the Plan
Administrator shall determine.

 

	6.2	Evidence of Awards 

 

Awards granted under the Plan shall be evidenced by a written, including
an electronic, instrument that shall contain such terms, conditions, limitations and restrictions as the Plan Administrator shall deem
advisable and that are not inconsistent with the Plan.

 

	6.3	Dividends and Distributions 

 

Participants may, if the Plan Administrator so determines, be credited
with dividends or dividend equivalents paid with respect to Class A Ordinary Shares underlying an Award in a manner determined by
the Plan Administrator in its sole discretion. The Plan Administrator may apply any restrictions to the dividends or dividend equivalents
that the Plan Administrator deems appropriate. The Plan Administrator, in its sole discretion, may determine the form of payment of dividends
or dividend equivalents, including cash, Class A Ordinary Shares, Restricted Share or Share Units.

 

    3

     

    

 

Notwithstanding the foregoing, the right to any
dividends or dividend equivalents declared and paid on the number of shares underlying an Option or Share Appreciation Right may not
be contingent, directly or indirectly, on the exercise of the Option or Share Appreciation Right, and must comply with or qualify for
an exemption under Section 409A.

 

Also notwithstanding the foregoing, the right to any dividends or dividend
equivalents declared and paid on Restricted Share must (a) be paid at the same time they are paid to other Shareholders and (b) comply
with or qualify for an exemption under Section 409A.

 

SECTION 7. OPTIONS 

 

	7.1	Grant of Options 

 

The Plan Administrator may grant Options designated as Incentive Share
Options or Nonqualified Share Options.

 

	7.2	Option Exercise Price 

 

Options shall be granted with an exercise price per share not less
than 100% of the Par Value of the Class A Ordinary Shares on the Grant Date.

 

	7.3	Term of Options 

 

Subject to earlier termination in accordance with the terms of the
Plan and the instrument evidencing the Option, the maximum term of an Option (the “Option Term”) shall be ten
years from the Grant Date. For Incentive Share Options, the Option Term shall be as specified in Section 8.4.

 

	7.4	Exercise of Options 

 

The Plan Administrator shall establish and set forth in each instrument
that evidences an Option the time at which, or the installments in which, the Option shall vest and become exercisable, any of which provisions
may be waived or modified by the Plan Administrator at any time. If not so established in the instrument evidencing the Option, the Option
shall vest and become exercisable according to the following schedule, which may be waived or modified by the Plan Administrator at any
time:

 

	
    Period of Participant’s Continuous

    Employment or Service With the

    Company or Its Related Companies

    From the Vesting Commencement Date
	 	
    Portion of Total Option That

    Is Vested and Exercisable

	After 1 year	 	1/4th
	
    After 2 years

    After 3 years
	 	
    An additional 1/4th

    An additional 1/4th

	After 4 years	 	100%

 

 

    4

     

    

 

To the extent an Option has vested and become exercisable, the Option
may be exercised in whole or from time to time in part by delivery to or as directed or approved by the Company of a properly executed
Share Option exercise agreement or notice, in a form and in accordance with procedures established by the Plan Administrator, setting
forth the number of shares with respect to which the Option is being exercised, the restrictions imposed on the shares purchased under
such exercise agreement or notice, if any, and such representations and agreements as may be required by the Plan Administrator, accompanied
by payment in full as described in Section 7.5. An Option may be exercised only for whole shares and may not be exercised for less
than a reasonable number of shares at any one time, as determined by the Plan Administrator.

 

	7.5	Payment of Exercise Price 

 

The exercise price for shares purchased under an Option shall be paid
in full to the Company by delivery of consideration equal to the product of the Option exercise price and the number of shares purchased.
Such consideration must be paid before the Company will issue the shares being purchased and must be in a form or a combination of forms
acceptable to the Plan Administrator for that purchase, which forms may include:

 

	(a)	cash;

 

	(b)	check or wire transfer;

 

	(c)	such other consideration as the Plan Administrator may permit.

 

In addition, to assist a Participant (including directors and executive
officers) in acquiring Class A Ordinary Shares pursuant to an Option granted under the Plan, the Plan Administrator, in its sole
discretion and to the extent permitted by applicable law, may authorize, either at the Grant Date or at any time before the acquisition
of Class A Ordinary Shares pursuant to the Option, (i) the payment by a Participant of the purchase price of the Class A
Ordinary Shares by a promissory note or (ii) the guarantee by the Company of a loan obtained by the Participant from a third party.
Such notes or loans must be full recourse to the extent necessary to avoid adverse accounting charges to the Company’s earnings
for financial reporting purposes. Subject to the foregoing, the Plan Administrator shall in its sole discretion specify the terms of any
loans or loan guarantees, including the interest rate and terms of and security for repayment.

 

    5

     

    

 

	7.6	Effect of Termination of Service 

 

The Plan Administrator shall establish and set forth in each instrument
that evidences an Option whether the Option shall continue to be exercisable, and the terms and conditions of such exercise, after a Termination
of Service, any of which provisions may be waived or modified by the Plan Administrator at any time. If not so established in the instrument
evidencing the Option, the Option shall be exercisable according to the following terms and conditions, which may be waived or modified
by the Plan Administrator at any time:

 

	(a)	Any portion of an Option that is not vested and exercisable on the date of a Participant’s Termination of Service shall expire on such date.

 

	(b)	Any portion of an Option that is vested and exercisable on the date of a Participant’s Termination of Service shall expire on the earliest to occur of:

 

	 	(i)	if the Participant’s Termination of Service occurs for reasons other than Cause, Retirement, Disability or death, the date that is two months after such Termination of Service;

 

	 	(ii)	if the Participant’s Termination of Service occurs by reason of Retirement or Disability, the date that is six months after such Termination of Service;

 

	 	(iii)	if the Participant’s Termination of Service occurs by death, the date that is one year after such Termination of Service; and

 

	 	(iv)	the Option Expiration Date.

 

Notwithstanding the foregoing, if a Participant dies after his or her
Termination of Service but while an Option is otherwise exercisable, the portion of the Option that is vested and exercisable on the date
of such Termination of Service shall expire upon the earlier to occur of (y) the Option Expiration Date and (z) the one-year
anniversary of the date of death, unless the Plan Administrator determines otherwise.

 

    6

     

    

 

Also notwithstanding the foregoing, in case a
Participant’s Termination of Service occurs for Cause, all Options granted to the Participant shall automatically expire upon first
notification to the Participant of such termination, unless the Plan Administrator determines otherwise. If a Participant’s employment
or service relationship with the Company is suspended pending an investigation of whether the Participant shall be terminated for Cause,
all the Participant’s rights under any Option shall likewise be suspended during the period of investigation. If any facts that
would constitute termination for Cause are discovered after a Participant’s Termination of Service, any Option then held by the
Participant may be immediately terminated by the Plan Administrator, in its sole discretion.

 

SECTION 8. INCENTIVE SHARE OPTION LIMITATIONS

 

Notwithstanding any other provisions of the Plan to the contrary, the
terms and conditions of any Incentive Share Options shall in addition comply in all respects with Section 422 of the Code, or any
successor provision, and any applicable regulations thereunder, including, to the extent required thereunder, the following:

 

	8.1	Dollar Limitation 

 

To the extent the aggregate Fair Market Value (determined as of the
Grant Date) of Class A Ordinary Shares with respect to which a Participant’s Incentive Share Options become exercisable for
the first time during any calendar year (under the Plan and all other Share Option plans of the Company and its parent and subsidiary
corporations) exceeds $100,000, such portion in excess of $100,000 shall be treated as a Nonqualified Share Option. In the event the Participant
holds two or more such Options that become exercisable for the first time in the same calendar year, such limitation shall be applied
on the basis of the order in which such Options are granted.

 

	8.2	Eligible Employees 

 

Individuals who are not employees of the Company or one of its parent
or subsidiary corporations may not be granted Incentive Share Options.

 

	8.3	Exercise Price 

 

Incentive Share Options shall be granted with an exercise price per
share not less than 100% of the Par Value of the Class A Ordinary Shares on the Grant Date.

 

    7

     

    

 

	8.4	Option Term 

 

Subject to earlier termination in accordance with the terms of the
Plan and the instrument evidencing the Option, the maximum term of an Incentive Share Option shall not exceed ten years, and in the case
of an Incentive Share Option granted to a Ten Percent Shareholder, shall not exceed five years.

 

	8.5	Exercisability 

 

An Option designated as an Incentive Share Option shall cease to qualify
for favorable tax treatment as an Incentive Share Option to the extent it is exercised (if permitted by the terms of the Option) (a) more
than three months after the date of a Participant’s termination of employment if termination was for reasons other than death or
disability, (b) more than one year after the date of a Participant’s termination of employment if termination was by reason
of disability, or (c) more than six months following the first day of a Participant’s leave of absence that exceeds three months,
unless the Participant’s reemployment rights are guaranteed by statute or contract.

 

	8.6	Taxation of Incentive Share Options 

 

In order to obtain certain tax benefits afforded to Incentive Share
Options under Section 422 of the Code, the Participant must hold the shares acquired upon the exercise of an Incentive Share Option
for two years after the Grant Date and one year after the date of exercise.

 

A Participant may be subject to the alternative
minimum tax at the time of exercise of an Incentive Share Option. The Participant shall give the Company prompt notice of any disposition
of shares acquired on the exercise of an Incentive Share Option prior to the expiration of such holding periods.

 

	8.7	Code Definitions 

 

For the purposes of this Section 8, “disability,”
“parent corporation” and “subsidiary corporation” shall have the meanings attributed to those terms for purposes
of Section 422 of the Code.

 

	8.8	Promissory Notes 

 

The amount of any promissory note delivered pursuant to Section 7.5
in connection with an Incentive Share Option shall bear interest at a rate specified by the Plan Administrator, but in no case less than
the rate required to avoid imputation of interest (taking into account any exceptions to the imputed interest rules) for federal income
tax purposes.

 

    8

     

    

 

SECTION 9. SHARE APPRECIATION RIGHTS 

 

	9.1	Grant of Share Appreciation Rights 

 

The Plan Administrator may grant Share Appreciation Rights (SAR) to
Participants at any time on such terms and conditions as the Plan Administrator shall determine in its sole discretion. An SAR may be
granted in tandem with an Option or alone (“freestanding”). The grant price of a tandem SAR shall be equal to
the exercise price of the related Option. The grant price of a freestanding SAR shall be established in accordance with procedures for
Options set forth in Section 7.2. An SAR may be exercised upon such terms and conditions and for the term as the Plan Administrator
determines in its sole discretion; provided, however, that, subject to earlier termination in accordance with the terms of the Plan and
the instrument evidencing the SAR, the maximum term of a freestanding SAR shall be ten years, and in the case of a tandem SAR, (a) the
term shall not exceed the term of the related Option and (b) the tandem SAR may be exercised for all or part of the shares subject
to the related Option upon the surrender of the right to exercise the equivalent portion of the related Option, except that the tandem
SAR may be exercised only with respect to the shares for which its related Option is then exercisable.

 

	9.2	Payment of SAR Amount 

 

Upon the exercise of an SAR, a Participant shall be entitled to receive
payment in an amount determined by multiplying: (a) the difference between the Fair Market Value of the Class A Ordinary Shares
on the date of exercise over the grant price of the SAR by (b) the number of shares with respect to which the SAR is exercised. At
the discretion of the Plan Administrator as set forth in the instrument evidencing the Award, the payment upon exercise of an SAR may
be in cash, in shares, in some combination thereof or in any other manner approved by the Plan Administrator in its sole discretion.

 

	9.3	Waiver of Restrictions 

 

The Plan Administrator, in its sole discretion, may waive any other
terms, conditions or restrictions on any SAR under such circumstances and subject to such terms and conditions as the Plan Administrator
shall deem appropriate.

 

SECTION 10. SHARE AWARDS, RESTRICTED SHARE
AND SHARE UNITS 

 

	10.1	Grant of Share Awards, Restricted Share and Share Units 

 

The Plan Administrator may grant Share Awards, Restricted Share and
Share Units on such terms and conditions and subject to such repurchase or forfeiture restrictions, if any, which may be based on continuous
service with the Company or a Related Company or the achievement of any performance goals, as the Plan Administrator shall determine in
its sole discretion, which terms, conditions and restrictions shall be set forth in the instrument evidencing the Award.

 

    9

     

    

 

	10.2	Vesting of Restricted Share and Share Units 

 

Upon the satisfaction of any terms, conditions and restrictions prescribed
with respect to Restricted Share or Share Units, or upon a Participant’s release from any terms, conditions and restrictions of
Restricted Share or Share Units, as determined by the Plan Administrator (a) the shares of Restricted Share covered by each Award
of Restricted Share shall become freely transferable by the Participant subject to the terms and conditions of the Plan, the instrument
evidencing the Award, and applicable securities laws, and (b) Share Units shall be paid in Class A Ordinary Shares or, if set
forth in the instrument evidencing the Awards, in cash or a combination of cash and Class A Ordinary Shares. Any fractional shares
subject to such Awards shall be paid to the Participant in cash.

 

	10.3	Waiver of Restrictions 

 

The Plan Administrator, in its sole discretion, may waive the repurchase
or forfeiture period and any other terms, conditions or restrictions on any Restricted Share or Share Unit under such circumstances and
subject to such terms and conditions as the Plan Administrator shall deem appropriate.

 

SECTION 11. WITHHOLDING 

 

The Company may require the Participant to pay to the Company the amount
of (a) any taxes that the Company is required by applicable federal, state, local or foreign law to withhold with respect to the
grant, vesting or exercise of an Award (“tax withholding obligations”) and (b) any amounts due from the
Participant to the Company or to any Related Company (“other obligations”). Notwithstanding any other provision
of the Plan to the contrary, the Company shall not be required to issue any Class A Ordinary Shares or otherwise settle an Award
under the Plan until such tax withholding obligations and other obligations are satisfied.

 

The Plan Administrator may permit or require a Participant to satisfy
all or part of the Participant’s tax withholding obligations and other obligations by (a) paying cash to the Company, (b) having
the Company withhold an amount from any cash amounts otherwise due or to become due from the Company to the Participant, (c) having
the Company withhold a number of Class A Ordinary Shares that would otherwise be issued to the Participant (or become vested, in
the case of Restricted Share) having a Fair Market Value equal to the tax withholding obligations and other obligations, or (d) surrendering
a number of Class A Ordinary Shares the Participant already owns having a value equal to the tax withholding obligations and other
obligations. The value of the shares so withheld or tendered may not exceed the employer’s minimum required tax withholding rate.

 

    10

     

    

 

SECTION 12. ASSIGNABILITY 

 

No Award or interest in an Award may be sold, assigned, pledged (as
collateral for a loan or as security for the performance of an obligation or for any other purpose) or transferred by a Participant or
made subject to attachment or similar proceedings otherwise than by will or by the applicable laws of descent and distribution, except
to the extent the Participant designates one or more beneficiaries on a Company-approved form who may exercise the Award or receive payment
under the Award after the Participant’s death. During a Participant’s lifetime, an Award may be exercised only by the Participant.
Notwithstanding the foregoing and to the extent permitted by Section 422 of the Code, the Plan Administrator, in its sole discretion,
may permit a Participant to assign or transfer an Award, subject to such terms and conditions as the Plan Administrator shall specify.

 

SECTION 13. ADJUSTMENTS 

 

	13.1	Adjustment of Shares 

 

In the event, at any time or from time to time, a Share dividend, Share
split, spin-off, combination or exchange of shares, recapitalization, merger, consolidation, distribution to Shareholders other than a
normal cash dividend, or other change in the Company’s corporate or capital structure results in (a) the outstanding Class A
Ordinary Shares, or any securities exchanged therefor or received in their place, being exchanged for a different number or kind of securities
of the Company or (b) new, different or additional securities of the Company or any other company being received by the holders of
Class A Ordinary Shares, then the Plan Administrator shall make proportional adjustments in (i) the maximum number and kind
of securities available for issuance under the Plan; (ii) the maximum number and kind of securities issuable as Incentive Share Options
as set forth in Section 4.2(d); and (iii) the number and kind of securities that are subject to any outstanding Award and
the per share price of such securities, without any change in the aggregate price to be paid therefor. The determination by the Plan Administrator
as to the terms of any of the foregoing adjustments shall be conclusive and binding.

 

Notwithstanding the foregoing, the issuance by
the Company of shares of Share of any class, or securities convertible into shares of Share of any class, for cash or property, or for
labor or services rendered, either upon direct sale or upon the exercise of rights or warrants to subscribe therefor, or upon conversion
of shares or obligations of the Company convertible into such shares or other securities, shall not affect, and no adjustment by reason
thereof shall be made with respect to, outstanding Awards. Also notwithstanding the foregoing, a dissolution or liquidation of the Company
or a Change of Control shall not be governed by this Section 13.1 but shall be governed by Sections 13.2 and 13.3, respectively.

 

	13.2	Dissolution or Liquidation 

 

To the extent not previously exercised or settled, and unless otherwise
determined by the Plan Administrator in its sole discretion, Awards shall terminate immediately prior to the dissolution or liquidation
of the Company. To the extent a vesting condition, forfeiture provision or repurchase right applicable to an Award has not been waived
by the Plan Administrator, the Award shall be forfeited immediately prior to the commencement of the dissolution or liquidation.

 

    11

     

    

 

	13.3	Change of Control 

 

(a) Notwithstanding any other provision of the Plan to the contrary,
unless the Plan Administrator determines otherwise with respect to a particular Award in the instrument evidencing the Award or in a written
employment, services or other agreement between the Participant and the Company or a Related Company, in the event of a Change of Control,
if and to the extent an outstanding Award is not converted, assumed, substituted for or replaced by the Successor Company, then effective
immediately prior to the Change of Control such Award shall become fully vested and exercisable or payable, and all applicable restrictions
or forfeiture provisions shall lapse, and then terminate upon effectiveness of the Change of Control. If and to the extent the Successor
Company converts, assumes or replaces an outstanding Award, the vesting restrictions and/or forfeiture provisions applicable to such Award
shall not be accelerated or lapse, and all such vesting restrictions and/or forfeiture provisions shall continue with respect to any shares
of the Successor Company or other consideration that may be received with respect to such Award.

 

(b) For the purposes of Section 13.3(a), an Award shall be considered
converted, assumed, substituted for or replaced by the Successor Company if following the Change of Control the Award confers the right
to purchase or receive, for each Class A Ordinary Share subject to the Award immediately prior to the Change of Control, the consideration
(whether Share, cash or other securities or property) received in the Change of Control by holders of Class A Ordinary Shares for
each share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration
chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration received in the Change of
Control is not solely Class A Ordinary Shares of the Successor Company, the Plan Administrator may, with the consent of the Successor
Company, provide for the consideration to be received pursuant to the Award, for each Class A Ordinary Share subject thereto, to
be solely Class A Ordinary Shares of the Successor Company substantially equal in fair market value to the per share consideration
received by holders of Class A Ordinary Shares in the Change of Control. The determination of such substantial equality of value
of consideration shall be made by the Plan Administrator, and its determination shall be conclusive and binding.

 

(c) Notwithstanding the foregoing, the Plan Administrator,
in its sole discretion, may instead provide in the event of a Change of Control that a Participant’s outstanding Awards shall terminate
upon or immediately prior to such Change of Control and that each such Participant shall receive, in exchange therefor, a cash payment
equal to the amount (if any) by which (i) the Acquisition Price multiplied by the number of Class A Ordinary Shares subject
to such outstanding Awards (either to the extent then vested and exercisable, or subject to restrictions and/or forfeiture provisions,
or whether or not then vested and exercisable, or subject to restrictions and/or forfeiture provisions, as determined by the Plan Administrator
in its sole discretion) exceeds (ii) if applicable, the respective aggregate exercise, grant or purchase price payable with respect
to Class A Ordinary Shares subject to such Awards.

 

(d) For the avoidance of doubt, nothing in this
Section 14.3 requires all Awards to be treated similarly.

 

    12

     

    

 

	13.4	Further Adjustment of Awards 

 

Subject to Sections 13.2 and 13.3, the Plan Administrator shall
have the discretion, exercisable at any time before a sale, merger, consolidation, reorganization, liquidation, dissolution or change
of control of the Company, as defined by the Plan Administrator, to take such further action as it determines to be necessary or advisable
with respect to Awards. Such authorized action may include (but shall not be limited to) establishing, amending or waiving the type, terms,
conditions or duration of, or restrictions on, Awards so as to provide for earlier, later, extended or additional time for exercise, lifting
restrictions and other modifications, and the Plan Administrator may take such actions with respect to all Participants, to certain categories
of Participants or only to individual Participants. The Plan Administrator may take such action before or after granting Awards to which
the action relates and before or after any public announcement with respect to such sale, merger, consolidation, reorganization, liquidation,
dissolution or change of control that is the reason for such action.

 

	13.5	No Limitations 

 

The grant of Awards shall in no way affect the Company’s right
to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate
or sell or transfer all or any part of its business or assets.

 

	13.6	Fractional Shares 

 

In the event of any adjustment in the number of shares covered by any
Award, each such Award shall cover only the number of full shares resulting from such adjustment.

 

	13.7	Section 409A 

 

Subject to Section 17.5, but notwithstanding any other provision
of the Plan to the contrary, (a) any adjustments made pursuant to this Section 13 to Awards that are considered “deferred
compensation” within the meaning of Section 409A shall be made in compliance with the requirements of Section 409A and
(b) any adjustments made pursuant to this Section 13 to Awards that are not considered “deferred compensation” subject
to Section 409A shall be made in such a manner as to ensure that after such adjustment the Awards either (i) continue not to
be subject to Section 409A or (ii) comply with the requirements of Section 409A.

 

SECTION 14. FIRST REFUSAL AND REPURCHASE
RIGHTS; VOTING RESTRICTIONS 

 

	14.1	First Refusal Rights 

 

Until the date on which the initial registration of the Class A
Ordinary Shares under Section 12(b) or 12(g) of the Exchange Act first becomes effective, the Company shall have the right of first
refusal with respect to any proposed sale or other disposition by a Participant of any Class A Ordinary Shares issued pursuant to
an Award. Such right of first refusal shall be exercisable in accordance with the terms and conditions established by the Plan Administrator
and set forth in the Share purchase agreement evidencing the purchase of the shares or, if applicable, in a shareholders agreement or
other similar agreement.

 

	14.2	Repurchase Rights for Vested Shares 

 

Until the date on which the initial registration of the Class A
Ordinary Shares under Section 12(b) or 12(g) of the Exchange Act first becomes effective, upon a Participant’s Termination
of Service, all vested Class A Ordinary Shares issued pursuant to an Award (whether issued before or after such Termination of Service)
shall be subject to repurchase by the Company, at the Company’s sole discretion, at the Fair Market Value of such shares on the
date of such repurchase. The terms and conditions upon which such repurchase right shall be exercisable (including the period and procedure
for exercise) shall be established by the Plan Administrator and set forth in the Share purchase agreement evidencing the purchase of
the shares.

 

    13

     

    

 

	14.3	Other Rights and Voting Restrictions 

 

Until the date on which the initial registration of the Class A
Ordinary Shares under Section 12(b) or 12(g) of the Exchange Act first becomes effective, the Plan Administrator may require a Participant,
as a condition to receiving shares under the Plan, to become a party to a Share purchase agreement and/or a shareholders agreement or
other similar agreement, in the form designated by the Plan Administrator, pursuant to which Participant grants to the Company and/or
its other shareholders certain rights, including but not limited to co-sale rights, and agrees to certain voting restrictions with respect
to the Shares acquired by Participant under the Plan.

 

	14.4	General 

 

The Company’s rights under this Section 14 are assignable
by the Company at any time.

 

SECTION 15. MARKET STANDOFF 

 

In the event of an underwritten public offering by the Company of its
equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s initial
public offering, no person may sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise
dispose of or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any shares issued pursuant
to an Award granted under the Plan without the prior written consent of the Company or its underwriters. Such limitations shall be in
effect for such period of time as may be requested by the Company or such underwriters; provided, however, that in no event shall such
period exceed (a) 180 days after the effective date of the registration statement for such public offering or (b) such longer
period requested by the underwriters as is necessary to comply with regulatory restrictions on the publication of research reports (including,
but not limited to, NYSE Rule 472 or NASD Conduct Rule 2711, or any successor rules). The limitations of this Section 15 shall in
all events terminate two years after the effective date of the Company’s initial public offering.

 

In the event of any Share split, Share dividend, recapitalization,
combination of shares, exchange of shares or other change affecting the Company’s outstanding Class A Ordinary Shares effected
as a class without the Company’s receipt of consideration, any new, substituted or additional securities distributed with respect
to the shares issued under the Plan shall be immediately subject to the provisions of this Section 15, to the same extent the shares
issued under the Plan are at such time covered by such provisions.

 

In order to enforce the limitations of this Section 15,
the Company may impose stop-transfer instructions with respect to the shares until the end of the applicable standoff period.

 

SECTION 16. AMENDMENT AND TERMINATION 

 

	16.1	Amendment, Suspension or Termination 

 

The Board may amend, suspend or terminate the Plan or any portion of
the Plan at any time and in such respects as it shall deem advisable; provided, however, that, to the extent required by applicable law,
regulation or Share exchange rule, Shareholder approval shall be required for any amendment to the Plan. Subject to Section 16.3,
the Board may amend the terms of any outstanding Award, prospectively or retroactively.

 

    14

     

    

 

	16.2	Term of the Plan 

 

The Plan shall have no fixed expiration date. After the Plan is terminated,
no future Awards may be granted, but Awards previously granted shall remain outstanding in accordance with their applicable terms and
conditions and the Plan’s terms and conditions. Notwithstanding the foregoing, no Incentive Share Options may be granted more than
ten years after the later of (a) the Initial Effective Date and (b) the adoption by the Board of any amendment to the Plan that
constitutes the adoption of a new plan for purposes of Section 422 of the Code.

 

	16.3	Consent of Participant 

 

The amendment, suspension or termination of the Plan or a portion thereof
or the amendment of an outstanding Award shall not, without the Participant’s consent, materially adversely affect any rights under
any Award theretofore granted to the Participant under the Plan. Any change or adjustment to an outstanding Incentive Share Option shall
not, without the consent of the Participant, be made in a manner so as to constitute a “modification” that would cause such
Incentive Share Option to fail to continue to qualify as an Incentive Share Option. Notwithstanding the foregoing, any adjustments made
pursuant to Section 13 shall not be subject to these restrictions.

 

Subject to Section 17.5, but notwithstanding
any other provision of the Plan to the contrary, the Board shall have broad authority to amend the Plan or any outstanding Award without
the consent of the Participant to the extent the Board deems necessary or advisable to comply with, or take into account, changes in
applicable tax laws, securities laws, accounting rules or other applicable law, rule or regulation.

 

SECTION 17. GENERAL 

 

	17.1	No Individual Rights 

 

No individual or Participant shall have any claim to be granted any
Award under the Plan, and the Company has no obligation for uniformity of treatment of Participants under the Plan.

 

Furthermore, nothing in the Plan or any Award granted under the Plan
shall be deemed to constitute an employment contract or confer or be deemed to confer on any Participant any right to continue in the
employ of, or to continue any other relationship with, the Company or any Related Company or limit in any way the right of the Company
or any Related Company to terminate a Participant’s employment or other relationship at any time, with or without cause.

 

    15

     

    

 

	17.2	Issuance of Shares 

 

Notwithstanding any other provision of the Plan to the contrary, the
Company shall have no obligation to issue or deliver any Class A Ordinary Shares under the Plan or make any other distribution of
benefits under the Plan unless, in the opinion of the Company’s counsel, such issuance, delivery or distribution would comply with
all applicable laws (including, without limitation, the requirements of the Securities Act or the laws of any state or foreign jurisdiction)
and the applicable requirements of any securities exchange or similar entity.

 

The Company shall be under no obligation to any Participant to register
for offering or resale or to qualify for exemption under the Securities Act, or to register or qualify under the laws of any state or
foreign jurisdiction, any Class A Ordinary Shares, security or interest in a security paid or issued under, or created by, the Plan,
or to continue in effect any such registrations or qualifications if made.

 

As a condition to the exercise of an Option or
any other receipt of Class A Ordinary Shares pursuant to an Award under the Plan, the Company may require (a) the Participant
to represent and warrant at the time of any such exercise or receipt that such shares are being purchased or received only for the Participant’s
own account and without any present intention to sell or distribute such shares and (b) such other action or agreement by the Participant
as may from time to time be necessary to comply with the federal, state and foreign securities laws. At the option of the Company, a
stop-transfer order against any such shares may be placed on the official Share books and records of the Company, and a legend indicating
that such shares may not be pledged, sold or otherwise transferred, unless an opinion of counsel is provided (concurred in by counsel
for the Company) stating that such transfer is not in violation of any applicable law or regulation, may be stamped on Share certificates
to ensure exemption from registration. The Plan Administrator may also require the Participant to execute and deliver to the Company
a purchase agreement or such other agreement as may be in use by the Company at such time that describes certain terms and conditions
applicable to the shares.

 

To the extent the Plan or any instrument evidencing an Award provides
for issuance of Share certificates to reflect the issuance of Class A Ordinary Shares, the issuance may be effected on a non-certificated
basis, to the extent not prohibited by applicable law or the applicable rules of any Share exchange.

 

    16

     

    

 

	17.3	Indemnification 

 

Each person who is or shall have been a member of the Board or a committee
appointed by the Board in accordance with Section 3.1 shall be indemnified and held harmless by the Company against and from any
loss, cost, liability or expense that may be imposed upon or reasonably incurred by such person in connection with or resulting from any
claim, action, suit or proceeding to which such person may be a party or in which such person may be involved by reason of any action
taken or failure to act under the Plan and against and from any and all amounts paid by such person in settlement thereof, with the Company’s
approval, or paid by such person in satisfaction of any judgment in any such claim, action, suit or proceeding against such person, unless
such loss, cost, liability or expense is a result of such person’s own willful misconduct or except as expressly provided by statute;
provided, however, that such person shall give the Company an opportunity, at its own expense, to handle and defend the same before such
person undertakes to handle and defend it on such person’s own behalf.

 

The foregoing right of indemnification shall not be exclusive of any
other rights of indemnification to which such person may be entitled under the Company’s articles of incorporation or bylaws, as
a matter of law, or otherwise, or of any power that the Company may have to indemnify or hold harmless.

 

	17.4	No Rights as a Shareholder 

 

Unless otherwise provided by the Plan Administrator or in the instrument
evidencing the Award or in a written employment, services or other agreement, no Award, other than a Share Award, shall entitle the Participant
to any cash dividend, voting or other right of a Shareholder unless and until the date of issuance under the Plan of the shares that are
the subject of such Award.

 

	17.5	Compliance with Laws and Regulations 

 

In interpreting and applying the provisions of the Plan, any Option
granted as an Incentive Share Option pursuant to the Plan shall, to the extent permitted by law, be construed as an “incentive Share
Option” within the meaning of Section 422 of the Code.

 

The Plan and Awards granted under the Plan are intended to be exempt
from the requirements of Section 409A to the maximum extent possible, whether pursuant to the short-term deferral exception described
in Treasury Regulation Section 1.409A-1(b)(4), the exclusion applicable to Share Options, Share appreciation rights and certain other
equity-based compensation under Treasury Regulation Section 1.409A-1(b)(5), or otherwise. To the extent Section 409A is applicable
to the Plan or any Award granted under the Plan, it is intended that the Plan and any Awards granted under the Plan comply with the deferral,
payout, plan termination and other limitations and restrictions imposed under Section 409A. Notwithstanding any other provision of
the Plan or any Award granted under the Plan to the contrary, the Plan and any Award granted under the Plan shall be interpreted, operated
and administered in a manner consistent with such intentions; provided, however, that the Plan Administrator makes no representations
that Awards granted under the Plan shall be exempt from or comply with Section 409A and makes no undertaking to preclude Section 409A
from applying to Awards granted under the Plan.

 

Without limiting the generality of the foregoing,
and notwithstanding any other provision of the Plan or any Award granted under the Plan to the contrary, with respect to any payments
and benefits under the Plan or any Award granted under the Plan to which Section 409A applies, all references in the Plan or any
Award granted under the Plan to the termination of the Participant’s employment or service are intended to mean the Participant’s
“separation from service,” within the meaning of Section 409A(a)(2)(A)(i) to the extent necessary to avoid subjecting
the Participant to the imposition of any additional tax under Section 409A.

 

    17

     

    

 

In addition, if the Participant is a “specified
employee,” within the meaning of Section 409A, then to the extent necessary to avoid subjecting the Participant to the imposition
of any additional tax under Section 409A, amounts that would otherwise be payable under the Plan or any Award granted under the
Plan during the six-month period immediately following the Participant’s “separation from service,” within the meaning
of Section 409A(a)(2)(A)(i), shall not be paid to the Participant during such period, but shall instead be accumulated and paid
to the Participant (or, in the event of the Participant’s death, the Participant’s estate) in a lump sum on the first business
day after the earlier of the date that is six months following the Participant’s separation from service or the Participant’s
death. Notwithstanding any other provision of the Plan to the contrary, the Plan Administrator, to the extent it deems necessary or advisable
in its sole discretion, reserves the right, but shall not be required, to unilaterally amend or modify the Plan and any Award granted
under the Plan so that the Award qualifies for exemption from or complies with Section 409A.

 

	17.6	Participants in Other Countries or Jurisdictions 

 

Without amending the Plan, the Plan Administrator may grant Awards
to Eligible Persons who are foreign nationals on such terms and conditions different from those specified in the Plan, as may, in the
judgment of the Plan Administrator, be necessary or desirable to foster and promote achievement of the purposes of the Plan and shall
have the authority to adopt such modifications, procedures, subplans and the like as may be necessary or desirable to comply with provisions
of the laws or regulations of other countries or jurisdictions in which the Company or any Related Company may operate or have employees
to ensure the viability of the benefits from Awards granted to Participants employed in such countries or jurisdictions, meet the requirements
that permit the Plan to operate in a qualified or tax efficient manner, comply with applicable foreign laws or regulations and meet the
objectives of the Plan.

 

	17.7	No Trust or Fund 

 

The Plan is intended to constitute an “unfunded” plan.
Nothing contained herein shall require the Company to segregate any monies or other property, or Class A Ordinary Shares, or to create
any trusts, or to make any special deposits for any immediate or deferred amounts payable to any Participant, and no Participant shall
have any rights that are greater than those of a general unsecured creditor of the Company.

 

	17.8	Successors 

 

All obligations of the Company under the Plan with respect to Awards
shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase,
merger, consolidation, or otherwise, of all or substantially all the business and/or assets of the Company.

 

    18

     

    

 

	17.9	Severability 

 

If any provision of the Plan or any Award is determined to be invalid,
illegal or unenforceable in any jurisdiction, or as to any person, or would disqualify the Plan or any Award under any law deemed applicable
by the Plan Administrator, such provision shall be construed or deemed amended to conform to applicable laws, or, if it cannot be so construed
or deemed amended without, in the Plan Administrator’s determination, materially altering the intent of the Plan or the Award, such
provision shall be stricken as to such jurisdiction, person or Award, and the remainder of the Plan and any such Award shall remain in
full force and effect.

 

	17.10	Choice of Law and Venue 

 

Any dispute, difference or claim arising out of or in connection with
this contract, shall be referred to and determined by arbitration in Hong Kong using the law of the United States or California to the
extent not governed by the law of the United States as the governing law. The Domestic Arbitration Rules of Hong Kong International Arbitration
Centre shall apply to the arbitration proceedings. The place of arbitration shall be in Hong Kong. There shall be only one arbitrator.
The language of the arbitration shall be English/Chinese.

 

	17.11	Legal Requirements 

 

The granting of Awards and the issuance of Class A Ordinary Shares
under the Plan are subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national
securities exchanges as may be required.

 

	17.12	California Appendix Provisions 

 

To the extent required by applicable law, Participants who are residents
of the State of California shall be subject to the additional terms and conditions set forth in Appendix B to the Plan until such
time as the Class A Ordinary Shares becomes a “listed” security under the Securities Act.

 

SECTION 18. EFFECTIVE DATE 

 

The effective date (the “Effective Date”)
is the date on which the Plan is adopted by the Board. If the Shareholders of the Company do not approve the Plan within 12 months
after the Board’s adoption of the Plan, any Incentive Share Options granted under the Plan will be treated as Nonqualified Share
Options.

 

    19

     

    

 

APPENDIX A 

 

DEFINITIONS 

 

As used in the Plan,

 

“Acquired Entity” means any entity acquired
by the Company or a Related Company or with which the Company or a Related Company merges or combines.

 

“Acquisition Price” means the fair market
value of the securities, cash or other property, or any combination thereof, receivable or deemed receivable upon a Change of Control
in respect of a Class A Ordinary Share, as determined by the Plan Administrator in its sole discretion.

 

“Award” means any Option, Share Appreciation
Right, Share Award, Restricted Share, Share Unit or cash-based award or other incentive payable in cash or in Class A Ordinary Shares,
as may be designated by the Plan Administrator from time to time.

 

“Board” means the Board
of Directors of the Company.

 

“Cause,” unless otherwise defined in the
instrument evidencing an Award or in a written employment, services or other agreement between the Participant and the Company or a Related
Company, means dishonesty, fraud, serious or willful misconduct, unauthorized use or disclosure of confidential information or trade secrets,
or conduct prohibited by law (except minor violations), in each case as determined by the Company’s chief human resources officer
or other person performing that function or, in the case of directors and executive officers, the Board, whose determination shall be
conclusive and binding.

 

“Change of Control,” unless the Plan Administrator
determines otherwise with respect to an Award at the time the Award is granted or unless otherwise defined for purposes of an Award in
a written employment, services or other agreement between the Participant and the Company or a Related Company, means consummation of:

 

	(a)	a merger or consolidation of the Company with or into any other company or other entity;

 

	(b)	a sale, in one transaction or a series of transactions undertaken with a common purpose, of at least 50% of the Company’s outstanding voting securities; or

 

	(c)	a sale, lease, exchange or other transfer, in one transaction or a series of related transactions, undertaken with a common purpose of at least 50%of the Company’s assets.

 

    A-1

     

    

 

Notwithstanding the foregoing, a Change of Control shall not include
(i) a merger or consolidation of the Company in which the holders of the outstanding voting securities of the Company immediately
prior to the merger or hold at least a majority of the outstanding voting securities of the Successor Company immediately after the merger
or consolidation;(ii) a sale, lease, exchange or other transfer of all or substantially all of the Company’s assets
to a majority-owned subsidiary company; or (iii) a transaction undertaken for the principal purpose of restructuring the capital
of the Company, including, but not limited to, reincorporating the Company in a different jurisdiction, converting the Company to a limited
liability company or creating a holding company; or (iv) any transaction that the Board determines is not a Change in Control for
purposes of the Plan.

 

Where a series of transactions undertaken with
a common purpose is deemed to be a Change of Control, the date of such Change of Control shall be the date on which the last of such
transactions is consummated.

 

“Code” means the Internal Revenue Code of
1986, as amended from time to time.

 

“Class A Ordinary Shares” means the Class A
Ordinary Shares of US $0.08 par value each of the Company.

 

“Company” means Horizon Business Intelligence
Co. Limited

 

“Disability,” unless otherwise defined by
the Plan Administrator for purposes of the Plan or in the instrument evidencing an Award or in a written employment, services or other
agreement between the Participant and the Company or a Related Company, means a mental or physical impairment of the Participant that
is expected to result in death or that has lasted or is expected to last for a continuous period of 12 months or more and that causes
the Participant to be unable to perform his or her material duties for the Company or a Related Company and to be engaged in any substantial
gainful activity, in each case as determined by the Company’s chief human resources officer or other person performing that function
or, in the case of directors and executive officers, the Board, each of whose determination shall be conclusive and binding.

 

    A-2

     

    

 

“Effective Date” has the meaning set forth
in Section 19.

 

“Eligible Person” means any person eligible
to receive an Award as set forth in Section 5.

 

“Exchange Act” means the Securities Exchange
Act of 1934, as amended from time to time.

 

“Fair Market Value” means the per share fair
market value of the Class A Ordinary Shares as established in good faith by the Plan Administrator or, if the Class A Ordinary
Shares are publicly traded, the closing price for the Class A Ordinary Shares on any given date during regular trading, or if not
trading on that date, such price on the last preceding date on which the Class A Ordinary Shares were traded, unless determined otherwise
by the Plan Administrator using such methods or procedures as it may establish.

 

“Grant Date” means the later of (a) the
date on which the Plan Administrator completes the corporate action authorizing the grant of an Award or such later date specified by
the Plan Administrator or (b) the date on which all conditions precedent to an Award have been satisfied, provided that conditions
to the exercisability or vesting of Awards shall not defer the Grant Date.

 

“Incentive Share Option”
means an Option granted with the intention that it qualify as an “incentive Share Option” as that term is defined for purposes
of Section 422 of the Code or any successor provision.

 

“Nonqualified Share Option” means an Option
other than an Incentive Share Option.

 

“Option” means a right to purchase Class A
Ordinary Shares granted under Section 7.

 

“Option Expiration Date” means the last day
of the maximum term of an Option.

 

“Option Term” means the maximum term of an
Option as set forth in Section 7.3.

 

“Participant” means any Eligible Person to
whom an Award is granted.

 

“Plan” means the ICZOOM Group Inc. Amended
and Restated 2015 Equity Incentive Plan.

 

    A-3

     

    

 

“Plan Administrator” has the meaning set
forth in Section 3.1.

 

“Related Company” means any entity that,
directly or indirectly, is in control of, is controlled by or is under common control with the Company.

 

“Restricted Share” means an Award of Class A
Ordinary Shares granted under Section 10, the rights of ownership of which are subject to restrictions prescribed by the Plan Administrator.

 

“Retirement,” unless otherwise defined in
the instrument evidencing the Award or in a written employment, services or other agreement between the Participant and the Company or
a Related Company, means “Retirement” as defined for purposes of the Plan by the Plan Administrator or the Company’s
chief human resources officer or other person performing that function or, if not so defined, means Termination of Service on or after
the date the Participant reaches “normal retirement age,” as that term is defined in Section 411(a)(8) of the Code.

 

“Section 409A” means Section 409A of
the Code.

 

“Securities Act” means
the Securities Act of 1933, as amended from time to time.

 

“Share Appreciation Right” or “SAR”
means a right granted under Section 9.1 to receive the excess of the Fair Market Value of a specified number of Class A Ordinary
Shares over the grant price.

 

“Share Award” means an Award of Class A
Ordinary Shares granted under Section 10, the rights of ownership of which are not subject to restrictions prescribed by the Plan
Administrator.

 

“Share Unit” means an Award denominated in
units of Class A Ordinary Shares granted under Section 10.

 

“Substitute Awards” means Awards granted
or Class A Ordinary Shares issued by the Company in substitution or exchange for awards previously granted by an Acquired Entity.

 

“Successor Company” means the surviving company,
the successor company, the acquiring company or its parent, as applicable, in connection with a Change of Control.

 

“Termination of Service”
means a termination of employment or service relationship with the Company or a Related Company for any reason, whether voluntary or
involuntary, including by reason of death, Disability or Retirement. Any question as to whether and when there has been a Termination
of Service for the purposes of an Award and the cause of such Termination of Service shall be determined by the Company’s chief
human resources officer or other person performing that function or, with respect to directors and executive officers, by the Board,
whose determination shall be conclusive and binding.

 

Transfer of a Participant’s employment or service relationship
between the Company and any Related Company shall not be considered a Termination of Service for purposes of an Award. Unless the Board
determines otherwise, a Termination of Service shall be deemed to occur if the Participant’s employment or service relationship
is with an entity that has ceased to be a Related Company. A Participant’s change in status from an employee of the Company or a
Related Company to a nonemployee director, consultant, advisor or independent contractor of the Company or a Related Company, or a change
in status from a nonemployee director, consultant, advisor or independent contractor of the Company or a Related Company to an employee
of the Company or a Related Company, shall not be considered a Termination of Service.

 

“Vesting Commencement Date”
means the Grant Date or such other date selected by the Plan Administrator as the date from which an Award begins to vest.

 

    A-4

     

    

 

APPENDIX B 

 

TO ICZOOM GROUP. INC. PLAN 

 

Amended and Restated 2015 Equity Incentive PLAN

 

(For California Residents Only)

 

This Appendix to the ICZOOM GROUP INC. Amended and Restated
2015 Equity Incentive Plan (the “Plan”) shall have application only to Participants who are residents of the
State of California. Capitalized terms contained herein shall have the same meanings given to them in the Plan, unless otherwise provided
in this Appendix. Notwithstanding any other provision of the Plan to the contrary and to the extent required by applicable law, the
following terms and conditions shall apply to all Awards granted to residents of the State of California, until such time as the Class A
Ordinary Shares becomes a “listed security” under the Securities Act:

 

1. Options shall have a term of not more than ten years from the Grant
Date.

 

2. Awards shall be nontransferable other than
by will or the laws of descent and distribution. Notwithstanding the foregoing, and to the extent permitted by Section 422 of the
Code, the Plan Administrator, in its discretion, may permit transfer of an Award to a revocable trust or as otherwise permitted by Rule
701 of the Securities Act.

 

3. Unless employment or services are terminated for Cause, the right
to exercise an Option in the event of Termination of Service, to the extent that the Participant is otherwise entitled to exercise an
Option on the date of Termination of Service, shall be

 

(a) at least six months from the date of a Participant’s
Termination of Service if termination was caused by death or Disability; and

 

(b) at least 30 days from the date of a Participant’s
Termination of Service if termination of employment was caused by other than death or Disability;

 

(c) but in no event later than the Option Expiration Date.

 

4. No Award may be granted to a resident of California
more than ten years after the earlier of the date of adoption of the Plan and the date the Plan is approved by the Shareholders.

 

5. Shareholders of the Company must approve the Plan by the later of
(a) within 12 months before or after the Plan is adopted by the Board and (b) (i) with respect to Options, prior to or
within 12 months of the grant of an Option under the Plan to a resident of the State of California, and (ii) with respect to Awards
other than Options, prior to the issuance of such Award to a resident of the State of California. Any Option exercised by a California
resident or shares issued under an Award to a California resident shall be rescinded if Shareholder approval is not obtained in the foregoing
manner. Shares subject to such Awards shall not be counted in determining whether such approval is obtained.

 

6. To the extent required by applicable law, the Company shall provide
annual financial statements of the Company to each California resident holding an outstanding Award under the Plan. Such financial statements
need not be audited and need not be issued to key persons whose duties at the Company assure them access to equivalent information.

 

    B-1

     

    

 

PLAN ADOPTION AND AMENDMENTS/ADJUSTMENTS 

 

SUMMARY PAGE 

 

	
    Date of

    Board Action
	 	Action	 	
    Section/Effect of

    Amendment
	 	
    Date of Shareholder

    Approval

	Oct 5, 2015	 	Initial Plan Adoption	 	 	 	Oct. 5, 2015
	 	 	 	 
	Board approval on Oct. 26, 2020	 	Amended and restated in connection with the change of the Company’s name	 	Change all references to the Company’s former name from ICZOOM GROUP INC. to ICZOOM Group Inc.	 	 

  

    B-2

     

    

 

AMENDMENT

 

TO

 

ICZOOM GROUP INC.

 

AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN

 

This Amendment (“Amendment”),
dated as of August 8, 2022, is made by ICZOOM Group Inc. (the “Company”) to the Amended and Restated 2015 Equity Incentive
Plan (the “Plan”).

 

WHEREAS, the Company
maintains the Plan to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors
of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company and to align
their interests and efforts to the long-term interests of the Company’s Shareholders;

 

WHEREAS, pursuant to
Section 16.1 of the Plan, the Board may amend any provision of the Plan at any time (subject to requirements under applicable laws, regulation
or share exchange rule); and

 

WHEREAS, the Company
desires to amend the Plan in connection with a share consolidation of the Company effectuated on August 8, 2022. All terms defined in
the Plan and used in this Amendment shall have the same meaning in this Amendment as in the Plan.

 

NOW, THEREFORE, the
Company hereby amends the Plan as follows:

 

	1.	Section 4.1 of the Plan is amended to read as follows:

 

“Subject to adjustment from time
to time as provided in Section 14.1, a maximum of 6,250,000 Class A Ordinary Shares shall be available for issuance under the Plan. Shares
issued under the Plan shall be drawn from authorized and unissued shares.

 

	2.	In Appendix A of Definition, the definition of the following term is amended to read as follows:

 

“Class A Ordinary
Shares” means the Class A Ordinary Shares of US $0.16 par value each of the Company.

 

	3.	Incorporation. This Amendment shall be and is hereby incorporated in and forms a part of the Plan.

 

	4.	Ratification. All other provisions of the Plan remain unchanged and are hereby ratified by the
Company.

 

[intentionally left blank]

 

[signature page follows]

 

     

     

    

 

IN WITNESS WHEREOF, the
Company hereto has executed this Amendment as of the day and year first set forth above.

 

	 	ICZOOM Group Inc.
	 	 
	 	By:	/s/ Lei Xia
	 	Name: 	Lei Xia
	 	Title:	Chief Executive Officer

 

[signature page to
Amendment to Plan]Exhibit
10.1

 

(i)
COMMON STOCK PURCHASE AGREEMENT

 

Dated
as of September 7, 2022

 

by
and between

 

AESTHER
HEALTHCARE ACQUISITION CORPORATION

 

and

 

WHITE
LION CAPITAL LLC

 

    	 

     

    

 

TABLE
OF CONTENTS

 

	Article
    I DEFINITIONS	1
	Article
    II PURCHASE AND SALE OF COMMON STOCK	2
	Section
    2.1   Purchase and Sale of Stock	2
	Section
    2.2   Closing Date	2
	Section
    2.3   Initial Public Announcements and Required Filings	2
	Article
    III PURCHASE TERMS	3
	Section
    3.1   Purchases	3
	Section
    3.2   Settlement	3
	Section
    3.3   Compliance with Rules of Trading Market	4
	Section
    3.4   Beneficial Ownership Limitation	4
	Article
    IV REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR	5
	Section
    4.1   Organization and Standing of the Investor	5
	Section
    4.2   Authorization and Power	5
	Section
    4.3   No Conflicts	5
	Section
    4.4   Investment Purpose	6
	Section
    4.5   Accredited Investor Status	6
	Section
    4.6   Reliance on Exemptions	6
	Section
    4.7   Information	6
	Section
    4.8   No Governmental Review	7
	Section
    4.9   No General Solicitation	7
	Section
    4.10   Not an Affiliate	7
	Section
    4.11   No Prior Short Sales	7
	Section
    4.12   Statutory Underwriter Status	7
	Section
    4.13   Resales of Shares	7
	Section
    4.14   Primary Place of Business	7
	Article
    V REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY	8
	Section
    5.1   Organization, Good Standing and Power	8
	Section
    5.2   Authorization, Enforcement	8
	Section
    5.3   Capitalization	8
	Section
    5.4   Issuance of Shares	9
	Section
    5.5   No Conflicts	9

 

    	 

     

    

 

	Section
    5.6   SEC Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting;
    Accountants	10
	Section
    5.7   Subsidiaries	11
	Section
    5.8   No Material Adverse Effect; Absence of Certain Changes	12
	Section
    5.9   No Material Defaults	12
	Section
    5.10   Material Contracts	12
	Section
    5.11   Solvency	12
	Section
    5.12   Real Property; Other Property	13
	Section
    5.13   Actions Pending	13
	Section
    5.14   Compliance with Law	13
	Section
    5.15   Certain Fees	13
	Section
    5.16   Disclosure	13
	Section
    5.17   Operation of Business	14
	Section
    5.18   Environmental Compliance	14
	Section
    5.19   No Improper Practices	15
	Section
    5.20   Transactions With Affiliates	15
	Section
    5.21   Labor Disputes	15
	Section
    5.22   Use of Proceeds	16
	Section
    5.23   Investment Company Act Status	16
	Section
    5.24   Reserved	16
	Section
    5.25   Taxes	16
	Section
    5.26   Insurance	16
	Section
    5.27   Exemption from Registration	16
	Section
    5.28   No General Solicitation or Advertising	17
	Section
    5.29   No Integrated Offering	17
	Section
    5.30   Dilutive Effect	17
	Section
    5.31   Manipulation of Price	17
	Section
    5.32   Listing and Maintenance Requirements; DTC Eligibility	17
	Section
    5.33   OFAC	18
	Section
    5.34   Information Technology; Compliance with Data Privacy Laws	18
	Section
    5.35   Acknowledgement Regarding Investor’s Acquisition of Shares	18
	Article
    VI ADDITIONAL COVENANTS	19
	Section
    6.1   Securities Compliance	19
	Section
    6.2   Reservation of Common Stock	19

 

    	 

     

    

 

	Section
    6.3   Registration and Listing	19
	Section
    6.4   Compliance with Laws	20
	Section
    6.5   Keeping of Records and Books of Account; Due Diligence	20
	Section
    6.6   No Frustration; No Variable Rate Transactions	21
	Section
    6.7   Corporate Existence	21
	Section
    6.8   Fundamental Transaction	21
	Section
    6.9   Selling Restrictions	21
	Section
    6.10   Effective Registration Statement	22
	Section
    6.11   Blue Sky	22
	Section
    6.12   Non-Public Information	22
	Section
    6.13   Broker/Dealer	22
	Section
    6.14   Disclosure Schedule	23
	Section
    6.15   Delivery of Bring Down Opinions and Compliance Certificates Upon Occurrence of Certain Events	24
	Article
    VII CONDITIONS TO CLOSING AND CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES	24
	Section
    7.1   Conditions Precedent to Closing	24
	Section
    7.2   Conditions Precedent to Commencement	25
	Section
    7.3   Conditions Precedent to Purchases after Commencement Date	28
	Article
    VIII TERMINATION	32
	Section
    8.1   Automatic Termination	32
	Section
    8.2   Other Termination	32
	Section
    8.3   Effect of Termination	32
	Article
    IX INDEMNIFICATION	33
	Section
    9.1   Indemnification	33
	Section
    9.2   Indemnification Procedures	34
	Article
    X MISCELLANEOUS	34
	Section
    10.1   Certain Fees and Expenses; Commitment Shares; Commencement Irrevocable Transfer Agent Instructions	34
	Section
    10.2   Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial	36
	Section
    10.3   Entire Agreement	37
	Section
    10.4   Notices	37
	Section
    10.5   Waivers	38
	Section
    10.6   Amendments	38
	Section
    10.7   Headings	38
	Section
    10.8   Construction	38
	Section
    10.9   Binding Effect	39
	Section
    10.10   No Third Party Beneficiaries	39
	Section
    10.11   Governing Law	39
	Section
    10.12   Survival	39
	Section
    10.13   Counterparts	39
	Section
    10.14   Publicity	39
	Section
    10.15   Severability	40
	Section
    10.16   Further Assurances	40
	Section
    10.17   Waiver of Claims Against Trust	40

 

    	 

     

    

 

COMMON
STOCK PURCHASE AGREEMENT

 

This
COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 7, 2022
(the “Execution Date”), by and between White Lion Capital, LLC, a Nevada limited liability company (the “Investor”),
and Aesther Healthcare Acquisition Corporation., a Delaware corporation (together with its successors, the “Company”).

 

RECITALS

 

WHEREAS,
the parties desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell
to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to $75,000,000 in aggregate
gross purchase price of newly issued shares of the Company’s Class A common stock, par value $0.0001 per share, or, following the
Merger, newly issued shares of the Company’s common stock, par value $0.0001 per share (collectively, the “Common Stock”).

 

WHEREAS,
such sales of Common Stock by the Company to the Investor will be made in reliance upon the provisions of Section 4(a)(2) of the Securities
Act (“Section 4(a)(2)”) and/or Rule 506(b) of Regulation D promulgated by the Commission under the Securities
Act (“Regulation D”), and upon such other exemption from the registration requirements of the Securities Act
as may be available with respect to any or all of the issuances and sales of Common Stock by the Company to the Investor to be made hereunder;

 

WHEREAS,
the parties hereto are concurrently entering into a Registration Rights Agreement in the form attached as Exhibit A hereto (the
“Registration Rights Agreement”), pursuant to which the Company shall register the resale of the Registrable
Securities (as defined in the Registration Rights Agreement), upon the terms and subject to the conditions set forth therein; and

 

WHEREAS,
in consideration for the Investor’s execution and delivery of this Agreement, the Company shall issue to the Investor the Commitment
Shares, pursuant to and in accordance with Section 10.1(ii);

 

NOW,
THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

 

Article
I

DEFINITIONS

 

Capitalized
terms used in this Agreement shall have the meanings ascribed to such terms in Annex I hereto, and hereby made a part hereof,
or as otherwise set forth in this Agreement.

 

    	1

     

    

 

Article
II

PURCHASE AND SALE OF COMMON STOCK

 

Section
2.1 Purchase and Sale of Stock. Upon the terms and subject to the conditions of this Agreement, and subject to the limitation
set forth in Section 3.3(a), during the Commitment Period, the Company, in its sole discretion, shall have the right, but not
the obligation, to issue and sell to the Investor up to $75,000,000 (the “Total Commitment”) in aggregate gross
purchase price of duly authorized, validly issued, fully paid and non-assessable Shares, and the Investor shall purchase such Shares
from the Company subject to the Exchange Cap and the other terms of this Agreement.

 

Section
2.2 Closing Date. This Agreement shall become effective and binding (the “Closing”) upon (a) the
delivery of counterpart signature pages of this Agreement and the Registration Rights Agreement executed by each of the parties hereto
and thereto, and (b) the delivery of all other documents, instruments and writings required to be delivered at the Closing, in each case
as provided in clause (iii) of Section 7.1, on the Closing Date.

 

Section
2.3 Initial Public Announcements and Required Filings. The Company shall, no later than four (4) Trading Days after the Execution
Date, file with the Commission a Current Report on Form 8-K disclosing the execution of this Agreement and the Registration Rights Agreement
by the Company and the Investor and describing the material terms thereof, including, without limitation, the Commitment Shares payable
by the Company to the Investor in accordance with Section 10.1(ii), disclosing any other material, nonpublic information delivered
to the Investor (or the Investor’s representatives or agents) by the Company or any of its Subsidiaries, or any of their respective
officers, directors, employees, agents or representatives (if any) in connection with the negotiation of this Agreement and the Registration
Rights Agreement, and attaching as exhibits thereto copies of each of this Agreement and the Registration Rights Agreement (including
all exhibits thereto, the “Current Report”). The Company shall provide the Investor a reasonable opportunity
to comment on a draft of the Current Report prior to filing the Current Report with the Commission and shall give due consideration to
all such comments. The Investor covenants that until such time as the transactions contemplated by this Agreement and the Registration
Rights Agreement are publicly disclosed by the Company as described in this Section 2.3, the Investor shall maintain the confidentiality
of all disclosures made to it in connection with the transactions contemplated by the Transaction Documents (including the existence
and terms of the transactions contemplated hereby and thereby), except that the Investor may disclose the terms of such transactions
to its financial, accounting, legal and other advisors (provided that the Investor directs such Persons to maintain the confidentiality
of such information, and that the Investor has taken commercially reasonable actions to establish that such Persons are contractually
bound, or are subject to professional obligations, to maintain such confidentiality). The Company shall use its commercially reasonable
efforts to prepare and, as soon as practicable, file with the Commission the Initial Registration Statement and any New Registration
Statement covering the resale by the Investor of the Registrable Securities in accordance with the Securities Act and the Registration
Rights Agreement. At or before 8:30 a.m. (New York City time) on the second (2nd) Trading Day immediately following the Effective
Date of the Initial Registration Statement and any New Registration Statement (or any post-effective amendment thereto), the Company
shall use its commercially reasonable efforts to file with the Commission in accordance with Rule 424(b) under the Securities Act the
final Prospectus to be used in connection with sales pursuant to such Registration Statement (or post-effective amendment thereto).

 

    	2

     

    

 

Article
III

PURCHASE TERMS

 

Section
3.1 Purchases. Subject to the satisfaction of the conditions set forth in Section 7.3, the Company shall have the right,
but not the obligation, to direct the Investor, from time to time from and after the Commencement Date, by its delivery to the Investor
of a Purchase Notice, to purchase the applicable Purchase Notice Shares, not to exceed the applicable Purchase Notice Limit, at the applicable
Purchase Price in accordance with this Agreement (each such purchase, a “Purchase”). The Purchase required
under the applicable Purchase Notice shall occur one (1) Trading Day following the end of the applicable Valuation Period (the “Purchase
Settlement Date”). The Company may not, without the Investor’s prior written consent, deliver a Purchase Notice to
the Investor if the Company shall have previously delivered a Purchase Notice, and the applicable Purchase Settlement Date for such previous
Purchase Notice shall not yet have occurred including the delivery of applicable Purchase Notice Shares as evidenced by the receipt of
such Shares by the Investor as DWAC Shares. The Investor is obligated to accept each Purchase Notice prepared and delivered by the Company
in accordance with the terms of and subject to the satisfaction of the conditions contained in Section 7.3. The Company may not
deliver a Purchase Notice if the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the Purchase Notice
Date is less than the Floor Price. If the Company delivers any Purchase Notice directing the Investor to purchase Purchase Notice Shares
in excess of the applicable Purchase Notice Limit, such Purchase Notice shall be void ab initio to the extent of the amount by which
the Purchase Notice Shares set forth in such Purchase Notice exceeds such applicable Purchase Notice Limit, and the Investor shall have
no obligation to purchase such excess Shares in respect of such Purchase Notice; provided, however, that the Investor shall
remain obligated to purchase the applicable Purchase Notice Limit in such Purchase, subject to adjustments provided herein. Notwithstanding
the foregoing, the Company shall not deliver any Purchase Notices to the Investor during the PEA Period.

 

Section
3.2 Settlement. On or prior to 6:00 pm, New York City time on the last day of the Valuation Period for a corresponding Purchase
Notice, and subject to the Company delivering to its Transfer Agent an instruction letter with respect to the immediate issuance of the
applicable Purchase Notice Shares (and providing to the Investor a copy of such letter), the Investor shall deliver to a mutually selected
escrow agent, an amount in cash equal to the product of (a) the total applicable number of Purchase Notice Shares in such applicable
Purchase Notice and (b) the applicable Purchase Price for such Shares (the “Purchase Amount”), for full payment
for such Shares to be purchased by the Investor in such Purchase, which funds shall be released to the Company, via wire transfer of
immediately available funds, not later than 5:00 p.m., New York City time on the Purchase Settlement Date, provided that the Investor
has received the applicable Purchase Notice Shares as DWAC Shares. Receipt of the Shares constituting the applicable Purchase Notice
Shares in each Purchase Notice to the Investor as DWAC Shares must occur prior to 5:00 p.m., New York City time, on the applicable Purchase
Settlement Date (the “Delivery Cutoff”). In the event that any Purchase Notice Shares are not delivered prior
to the applicable Delivery Cutoff the Company shall immediately pay a late fee to the Investor equal to 105% of the excess (if any) of
Investor’s cost to purchase a number of shares of Common Stock equal to the number of shares that the Company failed to timely
deliver, over the portion of the Purchase Amount attributable to the shares of Common Stock that the Company failed to timely deliver.
The Company shall not issue any fraction of a share of Common Stock to the Investor in connection with any Purchase effected pursuant
to this Agreement. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such
fraction of a share of Common Stock down to the nearest whole share. All payments to be made by the Investor pursuant to this Agreement
shall be made by wire transfer of immediately available funds to such account as the Company may from time to time designate by written
notice to the Investor in accordance with the provisions of this Agreement.

 

    	3

     

    

 

Section
3.3 Compliance with Rules of Trading Market.

 

(a) Exchange
Cap. The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and the Investor shall not
purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving effect thereto, the
aggregate number of shares of Common Stock that would be issued pursuant to this Agreement and the transactions contemplated hereby
would exceed the greater of 19.99% of the combined shares of Common Stock plus the shares of the Company’s Class B common
stock, par value $0.0001 per share (the “Class B Stock”), in each case issued and outstanding immediately
prior to the execution of this Agreement, which number of shares shall be reduced, on a share-for-share basis, by the number of
shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the
transactions contemplated by this Agreement under applicable rules of the Trading Market (such maximum number of shares, the
“Exchange Cap”), (x) unless the Company’s stockholders have approved the issuance of Common Stock
pursuant to this Agreement in excess of the Exchange Cap in accordance with the applicable rules of the Trading Market, or (y)
unless, and solely to the extent that, the Average Price shall equal or exceed the Base Price. For the avoidance of doubt, the
Company may, but shall be under no obligation to, request its stockholders to approve the issuance of Common Stock pursuant to this
Agreement; provided, that if such stockholder approval is not obtained, the Exchange Cap shall be applicable for all purposes
of this Agreement and the transactions contemplated hereby at all times during the term of this Agreement.

 

(b) General.
The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement if such issuance or sale would reasonably
be expected to result in (A) a violation of the Securities Act or (B) a breach of the rules of the Trading Market. The provisions of
this Section 3.3 shall be implemented in a manner otherwise than in strict conformity with the terms of this Section
3.3 only if necessary to ensure compliance with the Securities Act and the applicable rules of the Trading Market.

 

Section
3.4 Beneficial Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall
not issue or sell, and the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated
with all other shares of Common Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d)
of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than 9.99%
of the outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). Upon the written or oral
request of the Investor, the Company shall promptly (but not later than the next business day on which the Transfer Agent is open for
business) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the Company
shall each cooperate in good faith in the determinations required under this Section 3.4 and the application of this Section
3.4. The Investor’s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the
resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent
manifest error. The provisions of this Section 3.4 shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 3.4 to the extent necessary to properly give effect to the limitations contained in this Section
3.4.

 

    	4

     

    

 

Article
IV

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR

 

The
Investor hereby makes the following representations, warranties and covenants to the Company as of the Execution Date, as of each Commencement
Date, and as of each Purchase Notice Date and Purchase Settlement Date:

 

Section
4.1 Organization and Standing of the Investor. The Investor is a limited liability company duly organized, validly existing
and in good standing under the laws of the State of Nevada.

 

Section
4.2 Authorization and Power. The Investor has the requisite limited liability company power and authority to enter into and
perform its obligations under this Agreement and the Registration Rights Agreement and to purchase or acquire the Shares in accordance
with the terms hereof. The execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary limited liability
company action, and no further consent or authorization of the Investor, its managers or its members is required. Each of this Agreement
and the Registration Rights Agreement has been duly executed and delivered by the Investor and constitutes a valid and binding obligation
of the Investor enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting generally
the enforcement of, creditor’s rights and remedies or by other equitable principles of general application (including any limitation
of equitable remedies).

 

Section
4.3 No Conflicts. The execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement
and the consummation by the Investor of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation
of such Investor’s certificate of formation, limited liability company agreement or other applicable organizational instruments,
(ii) conflict with, constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or
give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust,
indenture, note, bond, license, lease agreement, instrument or obligation to which the Investor is a party or is bound, or (iii) result
in a violation of any federal, state, local or foreign statute, rule, or regulation, or any order, judgment or decree of any court or
governmental agency applicable to the Investor or by which any of its properties or assets are bound or affected, except, in the case
of clauses (ii) and (iii), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would
not, individually or in the aggregate, prohibit or otherwise interfere with, in any material respect, the ability of the Investor to
enter into and perform its obligations under this Agreement and the Registration Rights Agreement. The Investor is not required under
any applicable federal, state or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or
registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this
Agreement and the Registration Rights Agreement or to purchase or acquire the Shares in accordance with the terms hereof; provided,
however, that for purposes of the representation made in this sentence, the Investor is assuming and relying upon the accuracy
of the relevant representations and warranties and the compliance with the relevant covenants and agreements of the Company in the Transaction
Documents to which it is a party.

 

    	5

     

    

 

Section
4.4 Investment Purpose. The Investor is acquiring the Shares for its own account, for investment purposes and not with a view
towards, or for resale in connection with, the public sale or distribution thereof, in violation of the Securities Act or any applicable
state securities laws; provided, however, that by making the representations herein, the Investor does not agree, or make
any representation or warranty, to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of
the Shares at any time in accordance with, or pursuant to, a registration statement filed pursuant to the Registration Rights Agreement
or an applicable exemption under the Securities Act. The Investor does not presently have any agreement or understanding, directly or
indirectly, with any Person to sell or distribute any of the Shares. As of the Execution Date the Investor has, and as of each Commencement
Date and Purchase Notice Date, Investor will have, sufficient cash and other financial resources (in each case, excluding any shares
of Common Stock) to perform all of its obligations under this Agreement and to consummate the transactions contemplated hereby and by
the other Transaction Documents.

 

Section
4.5 Accredited Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a)
of Regulation D.

 

Section
4.6 Reliance on Exemptions. The Investor understands that the Shares are being offered and sold to it in reliance on specific
exemptions from the registration requirements of U.S. federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements, acknowledgments and
understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the
Investor to acquire the Shares.

 

Section
4.7 Information. All materials relating to the business, financial condition, management and operations of the Company and
materials relating to the offer and sale of the Shares which have been requested by the Investor have been furnished or otherwise made
available to the Investor or its advisors, including, without limitation, the Commission Documents. The Investor understands that its
investment in the Shares involves a high degree of risk. The Investor is able to bear the economic risk of an investment in the Shares
and has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of a proposed
investment in the Shares. The Investor and its advisors have been afforded the opportunity to ask questions of and receive answers from
representatives of the Company concerning the financial condition and business of the Company and other matters relating to an investment
in the Shares. Neither such inquiries nor any other due diligence investigations conducted by the Investor or its advisors, if any, or
its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties
contained in this Agreement or in any other Transaction Document to which the Company is a party or the Investor’s right to rely
on any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction
contemplated hereby. The Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed
investment decision with respect to its acquisition of the Shares. The Investor understands that it (and not the Company) shall be responsible
for its own tax liabilities that may arise as a result of this investment or the transactions contemplated by this Agreement.

 

    	6

     

    

 

Section
4.8 No Governmental Review. The Investor understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment
in the Shares nor have such authorities passed upon or endorsed the merits of the offering of the Shares.

 

Section
4.9 No General Solicitation. The Investor is not purchasing or acquiring the Shares as a result of any form of general solicitation
or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Shares.

 

Section
4.10 Not an Affiliate. The Investor is not an officer, director or an Affiliate of the Company.

 

Section
4.11 No Prior Short Sales. At no time prior to the Execution Date has the Investor, its sole member, any of their respective
officers, or any entity managed or controlled by the Investor or its sole member, engaged in or effected, in any manner whatsoever, directly
or indirectly, for its own principal account, any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO
of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common
Stock.

 

Section
4.12 Statutory Underwriter Status. The Investor acknowledges that it will be disclosed as an “underwriter” and
a “selling stockholder” in each Registration Statement and in any Prospectus contained therein to the extent required by
applicable law and to the extent the Prospectus is related to the resale of Registrable Securities.

 

Section
4.13 Resales of Shares. The Investor represents, warrants and covenants that it will resell such Shares only pursuant to the
Registration Statement in which the resale of such Shares is registered under the Securities Act, in a manner described under the caption
“Plan of Distribution” in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and
state securities laws, rules and regulations. For the purposes hereof, and in accordance with Regulation SHO, the sale after delivery
of the Purchase Notice of such number of shares of Common Stock reasonably expected to be purchased under each Purchase Notice shall
not be deemed a Short Sale.

 

Section
4.14 Primary Place of Business. The Investor’s primary place of business is in the State of California.

 

    	7

     

    

 

Article
V

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY

 

Except
as expressly set forth otherwise in the Commission Documents, the Company hereby makes the following representations, warranties and
covenants to the Investor as of the Execution Date, as of each Commencement Date, and as of each Purchase Notice Date and Purchase Settlement
Date:

 

Section
5.1 Organization, Good Standing and Power. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has the corporate power and authority to own, lease or operate its assets and properties
and to conduct its business as now being conducted. The Company is duly licensed or qualified and in good standing (or equivalent status
as applicable) in each jurisdiction in which the assets owned or leased by it or the character of its activities require it to be licensed
or qualified or in good standing (or equivalent status as applicable), except where the failure to be so licensed or qualified, individually
or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.

 

Section
5.2 Authorization, Enforcement. The Company has the requisite corporate power and authority to enter into and perform its
obligations under each of the Transaction Documents to which it is a party and to issue the Shares in accordance with the terms hereof
and thereof. Except for approvals of the Company’s Board of Directors or a committee thereof as may be required in connection with
any issuance and sale of Shares to the Investor hereunder (which approvals shall be obtained prior to the delivery of any Purchase Notice),
the execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party and the consummation
by it of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate action, and
no further consent or authorization of the Company, its Board of Directors or its stockholders is required. Each of the Transaction Documents
to which the Company is a party has been duly executed and delivered by the Company and constitutes a valid and binding obligation of
the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting
generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application (including
any limitation of equitable remedies).

 

Section
5.3 Capitalization. The authorized capital stock of the Company and the shares thereof issued and outstanding were as set
forth in the Commission Documents as of the dates reflected therein. Except as set forth in the Commission Documents, this Agreement
and the Registration Rights Agreement, there are no agreements or arrangements under which the Company is obligated to register the sale
of any securities under the Securities Act. Except as set forth in the Commission Documents, no shares of Common Stock are entitled to
preemptive rights and there are no outstanding debt securities and no contracts, commitments, understandings, or arrangements by which
the Company is or may become bound to issue additional shares of the capital stock of the Company or options, warrants, scrip, rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable
for, any shares of capital stock of the Company other than those issued or granted in the ordinary course of business pursuant to the
Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer restrictions contained in agreements
entered into by the Company to sell restricted securities or as set forth in the Commission Documents, the Company is not a party to,
and it has no Knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except
as set forth in the Commission Documents, there are no securities or instruments containing anti-dilution or similar provisions that
will be triggered by this Agreement or any of the other Transaction Documents or the consummation of the transactions described herein
or therein. The Company has filed with the Commission true and correct copies of the Company’s Amended and Restated Certificate
of Incorporation as in effect on the Closing Date (the “Charter”), and the Company’s Bylaws as in effect
on the Closing Date (the “Bylaws”).

 

    	8

     

    

 

Section
5.4 Issuance of Shares. The Shares to be issued under this Agreement have been, or with respect to Shares to be purchased
by the Investor pursuant to a particular Purchase Notice, will be, prior to the delivery to the Investor hereunder of such Purchase Notice,
duly authorized by all necessary corporate action on the part of the Company. The Shares, if and when issued in accordance with this
Agreement, shall be validly issued and outstanding, fully paid and non-assessable and free from all liens, charges, taxes, security interests,
encumbrances, rights of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof, and the
Investor shall be entitled to all rights accorded to a holder of Common Stock. At or prior to Commencement, the Company shall have duly
authorized and reserved a number of shares of Common Stock equal to the Exchange Cap for issuance and sale as Shares to the Investor
pursuant to Purchases that may be effected by the Company, in its sole discretion, from time to time from and after the Commencement
Date, pursuant to this Agreement.

 

Section
5.5 No Conflicts. The execution, delivery and performance by the Company of each of the Transaction Documents to which it
is a party and the consummation by the Company of the transactions contemplated hereby and thereby do not and shall not (i) result in
a violation of any provision of the Company’s Charter or Bylaws, (ii) conflict with or constitute a material default (or an event
which, with notice or lapse of time or both, would become a material default) under, or give rise to any rights of termination, amendment,
acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument
or obligation to which the Company or any of its Subsidiaries is a party or is bound, (iii) result in a violation of any federal, state,
local or foreign statute, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries (including
federal and state securities laws and regulations and the rules and regulations of the Trading Market or applicable Eligible Market),
except, in the case of clauses (ii) and (iii), for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens,
charges, encumbrances and violations as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect. Except as specifically contemplated by this Agreement or the Registration Rights Agreement and as required under the Securities
Act, any applicable state securities laws and applicable rules of the Trading Market, the Company is not required under any federal,
state or local rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court
or governmental agency in order for it to execute, deliver or perform any of its obligations under the Transaction Documents to which
it is a party, or to issue the Shares to the Investor in accordance with the terms hereof and thereof (other than such consents, authorizations,
orders, filings or registrations as have been obtained or made prior to the Closing Date); provided, however, that, for
purposes of the representation made in this sentence, the Company is assuming and relying upon the accuracy of the representations and
warranties of the Investor in this Agreement and the compliance by it with its covenants and agreements contained in this Agreement and
the Registration Rights Agreement.

 

    	9

     

    

 

Section
5.6 SEC Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants.

 

(a)
Since September 14, 2021, the Company has timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under
the Exchange Act) all filings required to be filed with or furnished to the Commission by the Company under the Securities Act or
the Exchange Act, including those required to be filed with or furnished to the Commission under Section 13(a) or Section 15(d) of
the Exchange Act (the “SEC Documents”). As of the Execution Date, no Subsidiary of the Company is required
to file or furnish any report, schedule, registration, form, statement, information or other document with the Commission. As of its
filing date, each SEC Document filed with or furnished to the Commission prior to the Closing Date complied in all material respects
with the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations thereunder, and, as of
its filing date (or, if amended or superseded by a filing prior to the Closing Date, on the date of such amended or superseded
filing). Each Registration Statement, on the date it is filed with the Commission, on the date it is declared effective by the
Commission and on each Purchase Notice Date shall comply in all material respects with the requirements of the Securities Act
(including, without limitation, Rule 415 under the Securities Act) and shall not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading,
except that this representation and warranty shall not apply to statements in or omissions from such Registration Statement made in
reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the
Investor expressly for use therein. The Prospectus and each Prospectus Supplement required to be filed pursuant to this Agreement or
the Registration Rights Agreement after the Closing Date, when taken together, on its date and on each Purchase Notice Date shall
comply in all material respects with the requirements of the Securities Act (including, without limitation, Rule 424(b) under the
Securities Act) and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading, except that this representation and warranty shall not apply to statements in or omissions from the Prospectus or any
Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in
writing by or on behalf of the Investor expressly for use therein. Each SEC Document (other than the Initial Registration Statement
or any New Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto) to be filed with or
furnished to the Commission after the Closing Date and incorporated by reference in the Initial Registration Statement or any New
Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto required to be filed pursuant to
this Agreement or the Registration Rights Agreement (including, without limitation, the Current Report), when such document is filed
with or furnished to the Commission and, if applicable, when such document becomes effective, as the case may be, shall comply in
all material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and
local laws, rules and regulations applicable to it. The Commission has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Company under the Securities Act or the Exchange Act.

 

    	10

     

    

 

(b)
The consolidated financial statements of the Company included or incorporated by reference in the Commission Documents, together
with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company
and its then consolidated Subsidiaries as of the dates indicated, and the consolidated results of operations, cash flows and changes
in stockholders’ equity of the Company and its then consolidated Subsidiaries for the periods specified (subject, in the case
of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate)
and have been prepared in compliance with the published requirements of the Securities Act and the Exchange Act, as applicable, and
in conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a
consistent basis (except (i) for such adjustments to accounting standards and practices as are noted therein and (ii) in the case of
unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) during the periods
involved. The summary consolidated financial data included or incorporated by reference in the SEC Documents present fairly the
information shown therein and have been compiled on a basis consistent with that of the financial statements included or
incorporated by reference in the Commission Documents, as of and at the dates indicated. The pro forma condensed combined financial
statements and the pro forma combined financial statements and any other pro forma financial statements or data included or
incorporated by reference in the Commission Documents comply with the requirements of Regulation S-X of the Securities Act,
including, without limitation, Article 11 thereof, and the assumptions used in the preparation of such pro forma financial
statements and data are reasonable, the pro forma adjustments used therein are appropriate to give effect to the circumstances
referred to therein and the pro forma adjustments have been properly applied to the historical amounts in the compilation of those
statements and data. There are no financial statements (historical or pro forma) that are required to be included or incorporated by
reference in the Commission Documents that are not included or incorporated by reference as required. The Company and the
Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations
or any “variable interest entities” as that term is used in Accounting Standards Codification Paragraph 810-10-25-20),
not described in Commission Documents which are required to be described in the Commission Documents. All disclosures contained or
incorporated by reference in the Commission Documents, if any, regarding “non-GAAP financial measures” (as such term is
defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act and
Item 10 of Regulation S-K under the Securities Act, to the extent applicable.

 

(c)
The Company has timely filed all certifications and statements the Company is required to file under (i) Rule 13a-14 or Rule 15d-14
under the Exchange Act or (ii) 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) with respect to all Commission
Documents with respect to which the Company is required to file such certifications and statements thereunder.

 

Section
5.7 Subsidiaries.

 

(a)
Each Subsidiary of the Company has been duly formed or organized, is validly existing under the applicable laws of its jurisdiction
of incorporation or organization and has the organizational power and authority to own, lease and operate its assets and properties
and to conduct its business as it is now being conducted. Each of the Company’s Subsidiaries is duly licensed or qualified and
in good standing (or equivalent status as applicable) as a foreign corporation (or other entity, if applicable) in each jurisdiction
in which the assets owned or leased by it or the character of its activities require it to be licensed or qualified or in good
standing (or equivalent status as applicable), except where the failure to be so licensed or qualified, individually or in the
aggregate, has not had and would not be expected to have a Material Adverse Effect.

 

    	11

     

    

 

(b)
Except as set forth in the Commission Documents, as of the Closing Date and as of the Commencement Date, (i) the Company owns and
will own, directly or indirectly, the equity interests in its Subsidiaries as set forth in the Commission Documents, in each case,
free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, other than
restrictions imposed by applicable securities laws; and (ii) all equity interests in the Subsidiaries owned by the Company, directly
or indirectly, have been duly authorized, validly issued, fully paid and non-assessable.

 

Section
5.8 No Material Adverse Effect; Absence of Certain Changes. Except as disclosed in the Commission Documents, since the date
of the most recent audited financial statements of the Company included or incorporated by reference in the Commission Documents, (a)
there has not occurred any Material Adverse Effect, or any development that would result in a Material Adverse Effect, and (b) the Company
and its Subsidiaries have conducted their respective businesses in the ordinary course of business consistent with past practice in all
material respects.

 

Section
5.9 No Material Defaults. Except as set forth in the Commission Documents, neither the Company nor any Subsidiary has defaulted
on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually
or in the aggregate, would have a Material Adverse Effect. Since September 14, 2021, the Company has not filed a report pursuant to Section
13(a) or 15(d) of the Exchange Act indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred stock
or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults,
individually or in the aggregate, would have a Material Adverse Effect.

 

Section
5.10 Material Contracts. Neither the Company nor any of its Subsidiaries is in breach of or default in any respect under the
terms of any Material Contract and, to the Knowledge of the Company, as of the Execution Date, no other party to any Material Contract
is in breach of or default under the terms of any Material Contract, except, in each of the foregoing cases, as would not reasonably
be expected to have a Material Adverse Effect. Each Material Contract is in full force and effect and is a valid and binding obligation
of the Company or the Subsidiary of the Company that is party thereto and, to the Knowledge of the Company, is a valid and binding obligation
of each other party thereto, except, in each of the foregoing cases, as would not reasonably be expected to have a Material Adverse Effect.
The Company has not received any written notice of the intention of any other party to a Material Contract to terminate for default,
convenience or otherwise, or not renew, any Material Contract, except, in each of the foregoing cases, as would not reasonably be expected
to have a Material Adverse Effect.

 

Section
5.11 Solvency. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant
to Title 11 of the United States Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the Company
have any Knowledge that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation proceedings
or other proceedings for relief under Title 11 of the United States Code or any other federal or state bankruptcy law or any law for
the relief of debtors. The Company is financially solvent and is generally able to pay its debts as they become due.

 

    	12

     

    

 

Section
5.12 Real Property; Other Property.

 

(a)
Except as set forth in the Commission Documents, the Company and its Subsidiaries own, lease or otherwise have a valid right to use,
all real property that is material to its business, good and marketable title in fee simple to all real property owned by them that
is material to its business and good and marketable title in all personal property and equipment owned by them that is material to
its business, in each case free and clear of all Encumbrances, except for Permitted Encumbrances. The Company has not received
written notice of any proposed condemnation proceeding and, to the Knowledge of the Company, there is no condemnation proceeding
threatened with respect to any of its property or facilities that are material to the business of the Company and its
Subsidiaries.

 

Section
5.13 Actions Pending. There are no legal or governmental proceedings pending or, to the Knowledge of the Company, threatened
to which the Company or any Subsidiary is a party or to which any of the properties of the Company or any Subsidiary is subject (i) other
than proceedings accurately described in all material respects in the Commission Documents and proceedings that would not have a Material
Adverse Effect on the Company and its Subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations
under this Agreement or to consummate the transactions contemplated by the Commission Documents or (ii) that are required to be described
in the Commission Documents and are not so described; and there are no statutes, regulations, contracts or other documents that are required
to be described in any of the Commission Documents or to be filed as exhibits to any of the Commission Documents that are not described
or filed as required.

 

Section
5.14 Compliance with Law. The Company has not received written notice from any Person that it, or any of its Subsidiaries,
is not conducting its business in compliance with all laws, rules and regulations of the jurisdictions in which the Company or any of
its Subsidiaries is conducting business that are applicable to the Company or any of its Subsidiaries, or any of their respective businesses
or properties, except where such non-compliance with such laws, rules and regulations would not result in a Material Adverse Effect,
including, without limitation, the Company shall have obtained all permits and qualifications required by any applicable state securities
or “Blue Sky” laws for the offer and sale of the Shares by the Company to the Investor and the subsequent resale of the Registrable
Securities by the Investor (or shall have the availability of exemptions therefrom).

 

Section
5.15 Certain Fees. Neither the Company nor any Subsidiary has incurred any liability for any finder’s fees, brokerage
commissions or similar payments in connection with the transactions herein contemplated.

 

Section
5.16 Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided the Investor
or any of its agents, advisors or counsel with any information that constitutes or could reasonably be expected to constitute material,
nonpublic information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by
the Transaction Documents. The Company understands and confirms that the Investor will rely on the foregoing representations in effecting
resales of Shares under the Registration Statement.

 

    	13

     

    

 

Section
5.17 Operation of Business.

 

(a)
The Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals, permits and
other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state or local
governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct
of their respective businesses as currently conducted (the “Permits”), except where the failure to
possess, obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in
the Commission Documents, neither the Company nor any Subsidiary has received written notice of any proceeding relating to
revocation or modification of any such Permit or has any reason to believe that such Permit will not be renewed in the ordinary
course, except where the failure to obtain any such renewal would not, individually or in the aggregate, have a Material Adverse
Effect. This Section 5.17(a) does not relate to environmental matters, such items being the subject of Section
5.18.

 

(b)
The Company owns or possesses or has the right to use all Intellectual Property owned by the Company or any of its Subsidiaries or
used by the Company or any of its Subsidiaries in the conduct of their respective businesses as currently conducted, without any
known infringement or other violation of the Intellectual Property rights of any Person, except as would not reasonably be expected
to have a Material Adverse Effect. To the Knowledge of the Company, no product or service marketed or sold (or proposed to be
marketed or sold) by the Company infringes, misappropriates or otherwise violates any Intellectual Property rights of any other
Person, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its
Subsidiaries has received any written communications alleging that the Company or any of its Subsidiaries has infringed,
misappropriated or otherwise violated, or by conducting its business, would infringe, misappropriate or otherwise violate any
Intellectual Property of any other Person, except as would not reasonably be expected to have a Material Adverse Effect.

 

(c)
The Company and its Subsidiaries have taken commercially reasonable efforts to maintain the confidentiality of all material Trade
Secrets and other material confidential information of the Company and its Subsidiaries and any confidential information owned by
any Person to whom the Company or any of its Subsidiaries has a written confidentiality obligation, except as would not reasonably
be expected to have a Material Adverse Effect.

 

Section
5.18 Environmental Compliance. Except as set forth in the Commission Documents and except as would not reasonably be expected
to result in a Material Adverse Effect (a) the Company and each of its Subsidiaries is and at all times has been in compliance with all
Environmental Laws; (b) the Company and each of its Subsidiaries holds and is in compliance with all Environmental Permits required for
the operation of their respective business; (c) there has been no Release on, upon, into or from any site currently or, to the Knowledge
of the Company, heretofore owned, leased or otherwise operated by the Company or any of its Subsidiaries that requires any Remedial Action
pursuant to Environmental Law; (d) to the Knowledge of the Company, there have been no Hazardous Materials generated by the Company or
any of its Subsidiaries that have been disposed of by or on behalf of the Company or any Subsidiary at any site that has been included
in any published U.S. federal or state “Superfund” site list; (e) none of the Company or any of its Subsidiaries has received
any request for information arising under Environmental Laws regarding a property to which Hazardous Materials generated by the Company
or any of its Subsidiaries have been transported for disposal; (f) none of the Company or any of its Subsidiaries is a party to, nor
has received written notice of, any pending or threatened action, claim, suit, arbitration, litigation, proceeding or investigation (whether
civil, criminal or administrative) by or before any court or grand jury, any governmental authority or any arbitration or mediation tribunal
arising under Environmental Laws; and (h) none of the Company or any of its Subsidiaries is a party to any material judgment, order,
decree, settlement agreement, or similar arrangement imposing on it any liability or obligation, including the obligation to perform
Remedial Action, under any applicable Environmental Laws that remain unfulfilled, and has not assumed, by contract or operation of law,
the liabilities under Environmental Laws of any other Person.

 

    	14

     

    

 

Section
5.19 No Improper Practices. Except as would not reasonably be expected to have a Material Adverse Effect, (i) neither the
Company nor, to the Company’s Knowledge, the Subsidiaries, nor to the Company’s Knowledge, any of their respective executive
officers has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose
any contribution in violation of law) or made any contribution or other payment to any official of, or candidate for, any federal, state,
municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any law or of the character
required to be disclosed in the Commission Documents; (ii) no relationship, direct or indirect, exists between or among the Company or,
to the Company’s Knowledge, the Subsidiaries or any Affiliate of any of them, on the one hand, and the directors, officers and
stockholders of the Company or, to the Company’s Knowledge, the Subsidiaries, on the other hand, that is required by the Securities
Act to be described in the Commission Documents that is not so described; (iii) no relationship, direct or indirect, exists between or
among the Company or the Subsidiaries or any Affiliate of them, on the one hand, and the directors, officers, stockholders or directors
of the Company or, to the Company’s Knowledge, any of its Subsidiaries, on the other hand, that is required by the rules of FINRA
to be described in the Commission Documents that is not so described; (iv) except as disclosed in the Commission Documents, there are
no material outstanding loans or advances or material guarantees of indebtedness by the Company or, to the Company’s Knowledge,
any of its Subsidiaries to or for the benefit of any of their respective officers or directors or any of the members of the families
of any of them; and (v) neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any employee or agent
of the Company or any of its Subsidiaries has made any payment of funds of the Company or any of its Subsidiaries or received or retained
any funds in violation of any law, rule or regulation (including, without limitation, the U.S. Foreign Corrupt Practices Act of 1977),
which payment, receipt or retention of funds is of a character required to be disclosed in the Commission Documents.

 

Section
5.20 Transactions With Affiliates. No relationship, direct or indirect, exists between or among the Company or any of its
Subsidiaries on the one hand, and the directors, officers, trustees, managers, stockholders, partners, customers or suppliers of the
Company or any of the Subsidiaries on the other hand, which would be required by the Securities Act or the Exchange Act to be disclosed
in the Commission Documents, which is not so disclosed.

 

Section
5.21 Labor Disputes. None of the Company nor any of its Subsidiaries is bound by or subject to any collective bargaining or
similar agreement with any labor union, and, to the Knowledge of the Company, none of the employees, representatives or agents of the
Company or any of its Subsidiaries is represented by any labor union. The Company and its Subsidiaries have complied with all employment
laws applicable to employees of the Company and its Subsidiaries, except where non-compliance with any such employment laws would not
have a Material Adverse Effect.

 

    	15

     

    

 

Section
5.22 Use of Proceeds. The proceeds from the sale of the Shares by the Company to Investor shall be used by the Company in
the manner as will be set forth in the Prospectus included in any Registration Statement (and any post-effective amendment thereto) and
any Prospectus Supplement thereto filed pursuant to the Registration Rights Agreement.

 

Section
5.23 Investment Company Act Status. The Company is not, and as a result of the consummation of the transactions contemplated
by the Transaction Documents and the application of the proceeds from the sale of the Shares as will be set forth in the Prospectus included
in any Registration Statement (and any post-effective amendment thereto) and any Prospectus Supplement thereto filed pursuant to the
Registration Rights Agreement the Company will not be an “investment company” within the meaning of the Investment Company
Act of 1940, as amended.

 

Section
5.24 Reserved.

 

Section
5.25 Taxes. The Company and each of its Subsidiaries has filed all federal, state, local and foreign tax returns required
to be filed through the Execution Date or have requested extensions thereof (except where the failure to file would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect) and have paid all taxes required to be paid thereon (except
for cases in which the failure to file or pay would not reasonably be expected to have a Material Adverse Effect, or, except as currently
being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the Company),
and no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which have had a Material Adverse Effect,
nor does the Company have any notice or Knowledge of any tax deficiency which could reasonably be expected to be determined adversely
to the Company or any of its Subsidiaries and which would reasonably be expected to have a Material Adverse Effect.

 

Section
5.26 Insurance. Except as would not be material to the Company and its Subsidiaries taken as whole, the Company and its Subsidiaries
maintain insurance with insurers in such amounts and against such risks as the management of the Company has in good faith determined
to be prudent and appropriate, and all material insurance policies maintained by or for the benefit of the Company or any of its Subsidiaries
are in full force and effect.

 

Section
5.27 Exemption from Registration. Subject to, and in reliance on, the representations, warranties and covenants made herein
by the Investor, the offer and sale of the Shares in accordance with the terms and conditions of this Agreement is exempt from the registration
requirements of the Securities Act pursuant to Section 4(a)(2) and/or Rule 506(b) of Regulation D; provided, however, that
at the request of and with the express agreements of the Investor (including, without limitation, the representations, warranties and
covenants of Investor set forth in Section 4.9 through 4.13), the Shares to be issued from and after Commencement to or
for the benefit of the Investor pursuant to this Agreement shall be issued to the Investor or its designee only as DWAC Shares and will
not bear legends noting restrictions as to resale of such securities under federal or state securities laws, nor will any such securities
be subject to stop transfer instructions.

 

    	16

     

    

 

Section
5.28 No General Solicitation or Advertising. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Shares.

 

Section
5.29 No Integrated Offering. None of the Company, its Subsidiaries or any of their Affiliates, nor any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of the issuance of any of the Shares under the Securities Act, whether through integration with prior
offerings or otherwise, or cause this offering of the Shares to require approval of stockholders of the Company under any applicable
stockholder approval provisions, including, without limitation, under the rules and regulations of the Trading Market. None of the Company,
its Subsidiaries, their Affiliates nor any Person acting on their behalf will take any action or steps referred to in the preceding sentence
that would require registration of the issuance of any of the Shares under the Securities Act or cause the offering of any of the Shares
to be integrated with other offerings.

 

Section
5.30 Dilutive Effect. The Company is aware and acknowledges that issuance of the Shares could cause dilution to existing stockholders
and could significantly increase the outstanding number of shares of Common Stock. The Company further acknowledges that its obligation
to issue the Shares to be purchased by the Investor pursuant to a Purchase is, upon the Company’s delivery to the Investor of a
Purchase Notice for a Purchase in accordance with this Agreement, absolute and unconditional following the delivery of such Purchase
Notice to the Investor, regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders
of the Company.

 

Section
5.31 Manipulation of Price. Neither the Company nor any of its officers, directors or Affiliates has, and, to the Knowledge
of the Company, no Person acting on their behalf has, (i) taken, directly or indirectly, any action designed or intended to cause or
to result in the stabilization or manipulation of the price of any security of the Company, or which caused or resulted in, or which
would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the
Company, in each case to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company; provided that the Company makes no representation with respect to actions taken,
directly or indirectly, by Investor. Neither the Company nor any of its officers, directors or Affiliates will during the term of this
Agreement, and, to the Knowledge of the Company, no Person acting on their behalf will during the term of this Agreement, take any of
the actions referred to in the immediately preceding sentence.

 

Section
5.32 Listing and Maintenance Requirements; DTC Eligibility. The Common Stock is registered pursuant to Section 12(b) of the
Exchange Act, and the Company has taken no action designed to, or which to its Knowledge is likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not received notice from the Trading Market to the effect that the Company is not in compliance
with the listing or maintenance requirements of the Trading Market. The Common Stock is eligible for participation in the DTC book entry
system and has shares on deposit at DTC for transferred electronically to third parties via DTC through its Deposit/Withdrawal at Custodian
(“DWAC”) delivery system. The Company has not received notice from DTC to the effect that a suspension of,
or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to
the Common Stock is being imposed or is contemplated.

 

    	17

     

    

 

Section
5.33 OFAC. Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge,
any director, officer, employee, agent, Affiliate or representative of the Company, is a Person that is, or is owned or controlled by
a Person that is (i) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign
Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority
(collectively, “Sanctions”), nor (ii) located, organized or resident in a country or territory that is the subject of Sanctions
(including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria). Neither the Company nor any of its Subsidiaries will
knowingly, directly or indirectly, use the proceeds from the sale of Shares under this Agreement, or lend, contribute or otherwise make
available such proceeds to any Subsidiary, joint venture partner or other Person (a) to fund or facilitate any activities or business
of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions,
or (b) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering,
whether as underwriter, advisor, investor or otherwise). For the past five years, neither the Company nor any of its Subsidiaries have
knowingly engaged in, or are now knowingly engaged in, any dealings or transactions with any Person, or in any country or territory,
that at the time of the dealing or transaction is or was the subject of Sanctions.

 

Section
5.34 Information Technology; Compliance with Data Privacy Laws. (i)(x) To the knowledge of Company, there has been no security
breach or other compromise of any Company’s information technology and computer systems, networks, hardware, Software, data, equipment
or technology (collectively, “IT Systems and Data”) that would result in a Material Adverse Effect and (y)
the Company has not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in,
any security breach or other compromise to their IT Systems and Data that would result in a Material Adverse Effect; (ii) the Company
is presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court
or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification,
except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect; and (iii) the
Company has implemented backup and disaster recovery technology consistent with industry standards and practices.

 

Section
5.35 Acknowledgement Regarding Investor’s Acquisition of Shares. The Company acknowledges and agrees that the Investor
is acting solely in the capacity of an arm’s-length purchaser with respect to this Agreement and the transactions contemplated
by the Transaction Documents. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated by the Transaction Documents,
and any advice given by the Investor or any of its representatives or agents in connection therewith is merely incidental to the Investor’s
acquisition of the Shares. The Company further represents to the Investor that the Company’s decision to enter into the Transaction
Documents to which it is a party has been based solely on the independent evaluation of the transactions contemplated thereby by the
Company and its representatives. The Company acknowledges and agrees that the Investor has not made and does not make any representations
or warranties with respect to the transactions contemplated by the Transaction Documents other than those specifically set forth in Article
IV.

 

    	18

     

    

 

Article
VI

ADDITIONAL COVENANTS

 

The
Company covenants with the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for the
benefit of the other party, during the Commitment Period (and with respect to the Company, for the period following the termination of
this Agreement specified in Section 8.3 pursuant to and in accordance with Section 8.3):

 

Section
6.1 Securities Compliance. The Company shall notify the Commission and the Trading Market, if and as applicable, in accordance
with their respective rules and regulations, of the transactions contemplated by the Transaction Documents, and shall take all necessary
action, undertake all proceedings and obtain all registrations, permits, consents and approvals for the legal and valid issuance of the
Shares to the Investor in accordance with the terms of the Transaction Documents, as applicable.

 

Section
6.2 Reservation of Common Stock. The Company has available and the Company shall reserve and keep available at all times,
free of preemptive and other similar rights of stockholders, the requisite aggregate number of authorized but unissued shares of Common
Stock to enable the Company to timely effect the issuance, sale and delivery of all Shares to be issued, sold and delivered in respect
of each Purchase effected under this Agreement, at least prior to the delivery by the Company to the Investor of the applicable Purchase
Notice in connection with such Purchase. Without limiting the generality of the foregoing, as of the Commencement Date the Company shall
have reserved, out of its authorized and unissued Common Stock, a number of shares of Common Stock equal to the Exchange Cap solely for
the purpose of effecting Purchases under this Agreement. The number of shares of Common Stock so reserved for the purpose of effecting
Purchases under this Agreement may be increased from time to time by the Company from and after the Commencement Date, and such number
of reserved shares may be reduced from and after the Commencement Date only by the number of Shares actually issued, sold and delivered
to the Investor pursuant to any Purchase effected from and after the Commencement Date pursuant to this Agreement.

 

Section
6.3 Registration and Listing. The Company shall use its commercially reasonable efforts to cause the Common Stock to continue
to be registered as a class of securities under Sections 12(b) of the Exchange Act, and to comply with its reporting and filing obligations
under the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Securities Act or the Exchange
Act) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under the Exchange Act
or Securities Act, except as permitted herein. The Company shall use its commercially reasonable efforts to continue the listing and
trading of its Common Stock and the listing of the Shares purchased by the Investor hereunder on the Trading Market and to comply with
the Company’s reporting, filing and other obligations under the rules and regulations of the Trading Market. The Company shall
not take any action which could be reasonably expected to result in the delisting or suspension of the Common Stock on the Trading Market.
If the Company receives any final and non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall
be terminated on a date certain, the Company shall promptly (and in any case within 24 hours) notify the Investor of such fact in writing
and shall use its commercially reasonable efforts to cause the Common Stock to be listed or quoted on another Eligible Market.

 

    	19

     

    

 

Section
6.4 Compliance with Laws.

 

(i)
During the Commitment Period, the Company shall comply with applicable provisions of the Securities Act and the Exchange Act,
including Regulation M thereunder, applicable state securities or “Blue Sky” laws, and applicable listing rules of the
Trading Market or Eligible Market, in connection with the transactions contemplated by this Agreement and the Registration Rights
Agreement, except as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Company to
enter into and perform its obligations under this Agreement in any material respect or for Investor to conduct resales of Shares
under the Registration Statement in any material respect.

 

(ii)
The Investor shall comply with all laws, rules, regulations and orders applicable to the performance by it of its obligations under
this Agreement and its investment in the Shares, except as would not, individually or in the aggregate, prohibit or otherwise
interfere with the ability of the Investor to enter into and perform its obligations under this Agreement in any material respect.
Without limiting the foregoing, the Investor shall comply with all applicable provisions of the Securities Act and the Exchange Act,
including Regulation M thereunder, and all applicable state securities or “Blue Sky” laws, in connection with the
transactions contemplated by this Agreement and the Registration Rights Agreement.

 

Section
6.5 Keeping of Records and Books of Account; Due Diligence.

 

(i)
The Investor and the Company shall each maintain records showing the remaining Total Commitment, and the dates and Purchase Notice
for each Purchase.

 

(ii)
Subject to the requirements of Section 6.12, from time to time from and after the Closing Date, the Company shall make
available for inspection and review by the Investor during normal business hours and after reasonable notice, customary
documentation reasonably requested by the Investor and/or its appointed counsel or advisors to conduct due diligence; provided,
however, that after the Closing Date, the Investor’s continued due diligence shall not be a condition precedent to the
Company’s right to deliver to the Investor any Purchase Notice or the settlement thereof. Each party hereto agrees not to
disclose any Confidential Information of the other party to any third party without the prior written consent of the other party.
Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that
it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other
party.

 

    	20

     

    

 

Section
6.6 No Frustration; No Variable Rate Transactions.

 

(i) No
Frustration. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or
transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the
Company to perform its obligations under the Transaction Documents to which it is a party, including, without limitation, the
obligation of the Company to deliver the Shares to the Investor in respect of a Purchase. For the avoidance of doubt, nothing in
this Section 6.6(i) shall in any way limit the Company’s right to terminate this Agreement in accordance with Section
8.2 (subject in all cases to Section 8.3).

 

(ii) No
Variable Rate Transactions. The Company shall not effect or enter into an agreement to effect any issuance by the Company or any
of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate
Transaction, other than in connection with an Exempt Issuance. The Investor shall be entitled to seek injunctive relief against the
Company and its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages,
without the necessity of showing economic loss and without any bond or other security being required.

 

Section
6.7 Corporate Existence. The Company shall take all steps necessary to preserve and continue the corporate existence of the
Company; provided, however, that, except as provided in Section 6.8, nothing in this Agreement shall be deemed to
prohibit the Company from engaging in any Fundamental Transaction with another Person. For the avoidance of doubt, nothing in this Section
6.7 shall in any way limit the Company’s right to terminate this Agreement in accordance with Section 8.2 (subject in
all cases to Section 8.3).

 

Section
6.8 Fundamental Transaction. If a Purchase Notice has been delivered to the Investor and the transactions contemplated therein
have not yet been fully settled in accordance with the terms and conditions of this Agreement, the Company shall not effect any Fundamental
Transaction until the expiration of five (5) Trading Days following the Valuation Period for the applicable Purchase Notice.

 

Section
6.9 Selling Restrictions.

 

(i)
Except as expressly set forth below, the Investor covenants that from and after the Execution Date up to and including the Trading
Day immediately following the expiration or termination of this Agreement as provided in Article VIII (the
“Restricted Period”), none of the Investor, any of their respective officers, or any entity managed or
controlled by the Investor or its sole member (collectively, the “Restricted Persons” and each of the
foregoing is referred to herein as a “Restricted Person”) shall, directly or indirectly, (i) engage in any
Short Sales of the Common Stock or (ii) engage in any hedging transaction, which establishes a net short position with respect to
the Common Stock, with respect to each of clauses (i) and (ii) hereof, either for its own principal account or for the principal
account of any other Restricted Person. Notwithstanding the foregoing, it is expressly understood and agreed that nothing contained
herein shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person during the Restricted
Period from: (1) selling “long” (as defined under Rule 200 promulgated under Regulation SHO) the Shares; or (2) selling
a number of shares of Common Stock equal to the number of Shares that such Restricted Person is unconditionally obligated to
purchase under a pending Purchase Notice.

 

    	21

     

    

 

(ii)
In addition to the foregoing, in connection with any sale of Shares (including any sale permitted by paragraph (i) above), the
Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without limitation, the
requirements of the Securities Act and the Exchange Act.

 

Section
6.10 Effective Registration Statement. During the Commitment Period, the Company shall use its commercially reasonable efforts
to maintain the continuous effectiveness of the Initial Registration Statement and each New Registration Statement filed with the Commission
under the Securities Act for the applicable Registration Period pursuant to and in accordance with the Registration Rights Agreement.

 

Section
6.11 Blue Sky. The Company shall take such action, if any, as is necessary by the Company in order to obtain an exemption
for or to qualify the Shares for sale by the Company to the Investor pursuant to the Transaction Documents, and at the request of the
Investor, the subsequent resale of Registrable Securities by the Investor, in each case, under applicable state securities or “Blue
Sky” laws and shall provide evidence of any such action so taken to the Investor from time to time following the Closing Date;
provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 6.11, (y) subject
itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

 

Section
6.12 Non-Public Information. Neither the Company or any of its Subsidiaries, nor any of their respective directors, officers,
employees or agents shall disclose any material non-public information about the Company to the Investor, unless a simultaneous public
announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant
by the Company or any of its Subsidiaries, or any of their respective directors, officers, employees and agents (as determined in the
reasonable good faith judgment of the Investor), (i) the Investor shall promptly provide written notice of such breach to the Company
and (ii) after such notice has been provided to the Company and, provided that the Company shall have failed to demonstrate to the Investor
in writing within 24 hours that such information does not constitute material, non-public information or the Company shall have failed
to publicly disclose such material, non-public information within 24 hours following demand therefor by the Investor, in addition to
any other remedy provided herein or in the other Transaction Documents, if the Investor is holding any Shares at the time of the disclosure
of material, non-public information, the Investor shall have the right to make a public disclosure, in the form of a press release, public
advertisement or otherwise, of such material, non-public information without the prior approval by the Company, any of its Subsidiaries,
or any of their respective directors, officers, employees or agents. The Investor shall not have any liability to the Company, any of
its Subsidiaries, or any of their respective directors, officers, employees, stockholders or agents, for any such disclosure.

 

Section
6.13 Broker/Dealer. The Investor shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that
it may purchase or otherwise acquire from the Company pursuant to the Transaction Documents, as applicable, which (or whom) shall be
a DTC participant (collectively, the “Broker-Dealer”). The Investor shall, from time to time, provide the Company
and the Transfer Agent with all information regarding the Broker-Dealer reasonably requested by the Company. The Investor shall be solely
responsible for all fees and commissions of the Broker-Dealer (if any), which shall not exceed customary brokerage fees and commissions
and shall be responsible for designating only a DTC participant eligible to receive DWAC Shares.

 

    	22

     

    

 

Section
6.14 Disclosure Schedule.

 

(i)
The Company may, from time to time, update a disclosure schedule (the “Disclosure Schedule”) as may be
required to satisfy the conditions set forth in Section 7.2(i) and Section 7.3(i) (to the extent such condition set
forth in Section 7.3(i) relates to the condition in Section 7.2(i) as of a specific Purchase Condition Satisfaction
Time). For purposes of this Section 6.14, any disclosure made in a schedule to the Compliance Certificate shall be deemed to
be an update of the Disclosure Schedule. Notwithstanding anything in this Agreement to the contrary, no update to the Disclosure
Schedule pursuant to this Section 6.14 shall cure any breach of a representation or warranty of the Company contained in this
Agreement and made prior to the update and shall not affect any of the Investor’s rights or remedies with respect
thereto.

 

(ii)
Notwithstanding anything to the contrary contained in the Disclosure Schedule or in this Agreement, the information and disclosure
contained in any Schedule of the Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other
Schedule of the Disclosure Schedule as though fully set forth in such Schedule for which applicability of such information and
disclosure is readily apparent on its face. The fact that any item of information is disclosed in the Disclosure Schedule shall not
be construed to mean that such information is required to be disclosed by this Agreement. Except as expressly set forth in this
Agreement, such information and the thresholds (whether based on quantity, qualitative characterization, dollar amounts or
otherwise) set forth herein shall not be used as a basis for interpreting the terms “material” or “Material
Adverse Effect” or other similar terms in this Agreement.

 

    	23

     

    

 

Section
6.15 Delivery of Bring Down Opinions and Compliance Certificates Upon Occurrence of Certain Events. Within three (3) Trading
Days immediately following (i) the end of each PEA Period, if the Company is required under the Securities Act to file with the Commission
(A) a post-effective amendment to the Initial Registration Statement required to be filed by the Company with the Commission pursuant
to Section 2(a) of the Registration Rights Agreement, (B) a New Registration Statement required to be filed by the Company with the Commission
pursuant to Section 2(c) of the Registration Rights Agreement, or (C) a post-effective amendment to a New Registration Statement required
to be filed by the Company with the Commission pursuant to Section 2(c) of the Registration Rights Agreement, in each case with respect
to a fiscal year ending after the Commencement Date, to register the resale of Shares by the Investor under the Securities Act pursuant
to this Agreement and the Registration Rights Agreement, and (ii) the date the Company files with the Commission (A) a Prospectus Supplement
to the Prospectus contained in the Initial Registration Statement or any New Registration Statement under the Securities Act, (B) an
annual report on Form 10-K under the Exchange Act with respect to a fiscal year ending after the Commencement Date, (C) an amendment
on Form 10-K/A to an annual report on Form 10-K under the Exchange Act with respect to a fiscal year ending after the Commencement Date,
which contains amended material financial information (or a restatement of material financial information) or an amendment to other material
information contained in a previously filed Form 10-K, and (D) a Commission Document under the Exchange Act (other than those referred
to in clauses (ii)(A) and (ii)(B) of this Section 6.15), which contains amended material financial information (or a restatement of material
financial information) or an amendment to other material information contained or incorporated by reference in the Initial Registration
Statement, any New Registration Statement, or the Prospectus or any Prospectus Supplement contained in the Initial Registration Statement
or any New Registration Statement (it being hereby acknowledged and agreed that the filing by the Company with the Commission of a quarterly
report on Form 10-Q that includes only updated financial information as of the end of the Company’s most recent fiscal quarter
shall not, in and of itself, constitute an “amendment” or “restatement” for purposes of clause (ii) of this Section
6.15), in each case of this clause (ii) if the Company is not also then required under the Securities Act to file a post-effective amendment
to the Initial Registration Statement, any New Registration Statement or a post-effective amendment to any New Registration Statement,
in each case with respect to a fiscal year ending after the Commencement Date, to register the resale of Shares by the Investor under
the Securities Act pursuant to this Agreement and the Registration Rights Agreement, and in any case of this clause (ii), not more than
once per calendar quarter, the Company shall (I) deliver to the Investor a Compliance Certificate, dated such date, and (II) cause to
be furnished to the Investor an opinion “bring-down” from outside counsel to the Company substantially in the form mutually
agreed to by the Company and the Investor prior to the Execution Date, modified, as necessary, to relate to such Registration Statement
or post-effective amendment, or the Prospectus contained therein as then amended or supplemented by such Prospectus Supplement, as applicable
(each such opinion, a “Bring-Down Opinion”) and (III) cause to be furnished to the Investor a comfort letter
“bring-down” from the independent registered public accountants of the Company, modified, as necessary, to relate to such
Registration Statement or post-effective amendment, or the Prospectus contained therein as then amended or supplemented by such Prospectus
Supplement, as applicable.

 

Article
VII

CONDITIONS TO CLOSING AND CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES

 

Section
7.1 Conditions Precedent to Closing. The Closing is subject to the satisfaction of each of the conditions set forth in this
Section 7.1 on the Closing Date.

 

(i) Accuracy
of the Investor’s Representations and Warranties. The representations and warranties of the Investor contained in this
Agreement (a) that are not qualified by “materiality” shall be true and correct in all material respects as of the
Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations
and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by
“materiality” shall be true and correct as of the Closing Date, except to the extent such representations and warranties
are as of another date, in which case, such representations and warranties shall be true and correct as of such other
date.

 

(ii) Accuracy
of the Company’s Representations and Warranties. Except as expressly set forth otherwise in the Commission Documents,
the representations and warranties of the Company contained in this Agreement (a) that are not qualified by
“materiality” or “Material Adverse Effect” shall be true and correct in all material respects as of the
Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations
and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by
“materiality” or “Material Adverse Effect” shall be true and correct as of the Closing Date, except to the
extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true
and correct as of such other date.

 

    	24

     

    

 

(iii) Closing
Deliverables. At the Closing, counterpart signature pages of this Agreement and the Registration Rights Agreement executed
by each of the parties hereto shall be delivered as provided in Section 2.2. Simultaneously with the execution and delivery
of this Agreement and the Registration Rights Agreement, the Investor’s counsel shall have received (a) the opinions of
outside counsel to the Company, dated the Closing Date, in the forms mutually agreed to by the Company and the Investor prior to the
Execution Date, and (b) the closing certificate from the Company, dated the Closing Date, in the form of Exhibit B
hereto.

 

Section
7.2 Conditions Precedent to Commencement. The right of the Company to commence delivering Purchase Notices under this Agreement,
and the obligation of the Investor to accept Purchase Notices delivered to the Investor by the Company under this Agreement (collectively,
“Commencement”), are subject to the initial satisfaction of each of the conditions set forth in this Section
7.2, with date upon which all such conditions have been satisfied referred to herein as the “Commencement Date.”

 

(i) Accuracy
of the Company’s Representations and Warranties. Except as expressly set forth otherwise in the Commission Documents,
the representations and warranties of the Company contained in this Agreement (a) that are not qualified by
“materiality” or “Material Adverse Effect” shall have been true and correct in all material respects as of
the Execution Date and shall be true and correct in all material respects as of the Commencement Date with the same force and effect
as if made on such date, except to the extent such representations and warranties are as of another date, in which case, such
representations and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified
by “materiality” or “Material Adverse Effect” shall have been true and correct when made and shall be true
and correct as of the Commencement Date with the same force and effect as if made on such date, except to the extent such
representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct
as of such other date.

 

(ii) Performance
of the Company. The Company shall have performed, satisfied and complied in all material respects with all covenants,
agreements and conditions precedent required by this Agreement and the Registration Rights Agreement to be performed, satisfied or
complied with by the Company at or prior to the Commencement. The Company shall have delivered to the Investor on or as of the
Commencement Date the compliance certificate substantially in the form attached hereto as Exhibit C (the
“Compliance Certificate”).

 

(iii) Initial
Registration Statement Effective. The Initial Registration Statement covering the resale by the Investor of the Registrable
Securities included therein required to be filed by the Company with the Commission pursuant to Section 2(a) of the Registration
Rights Agreement shall have been declared effective under the Securities Act by the Commission, and the Investor shall be permitted
to utilize the Prospectus therein to resell all of the Shares included in such Prospectus.

 

    	25

     

    

 

(iv) No
Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by the
Commission or any other federal or state governmental authority for any additional information relating to the Initial Registration
Statement, the Prospectus contained therein or any Prospectus Supplement thereto, or for any amendment of or supplement to the
Initial Registration Statement, the Prospectus contained therein or any Prospectus Supplement thereto, in each case to which the
Company shall not have responded to the satisfaction of the Commission or such other authority as evidenced in writing; (b) the
issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of
the Initial Registration Statement or prohibiting or suspending the use of the Prospectus contained therein or any Prospectus
Supplement thereto, or of the suspension of qualification or exemption from qualification of the Shares for offering or sale in any
jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; or (c) the occurrence of any event or
the existence of any condition or state of facts, which makes any statement of a material fact made in the Initial Registration
Statement, the Prospectus contained therein or any Prospectus Supplement thereto untrue or which requires the making of any
additions to or changes to the statements then made in the Initial Registration Statement, the Prospectus contained therein or any
Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary in
order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in the light of the
circumstances under which they were made) not misleading, or which requires an amendment to the Initial Registration Statement or a
supplement to the Prospectus contained therein or any Prospectus Supplement thereto to comply with the Securities Act or any other
law, in each case which additions, changes, amendments or supplements shall not have been made. The Company shall have no Knowledge
of any event that could reasonably be expected to have the effect of causing the suspension of the effectiveness of the Initial
Registration Statement or the prohibition or suspension of the use of the Prospectus contained therein or any Prospectus Supplement
thereto in connection with the resale of the Registrable Shares by the Investor.

 

(v) Other
Commission Filings. The Current Report shall have been filed with the Commission as required pursuant to Section 2.3.
The final Prospectus included in the Initial Registration Statement shall have been filed with the Commission prior to Commencement
in accordance with Section 2.3 and the Registration Rights Agreement. All reports, schedules, registrations, forms,
statements, information and other documents required to have been filed by the Company with the Commission pursuant to the reporting
requirements of the Exchange Act, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the
Exchange Act, prior to Commencement shall have been filed with the Commission.

 

(vi) No
Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended
by the Commission, the Trading Market or FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the Commencement Date), the Company shall not have received any final and
non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain
(unless, prior to such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall there have been
imposed any suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry
services by DTC with respect to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the
effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry
services by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or
restriction, DTC shall have notified the Company in writing that DTC has determined not to impose any such suspension or
restriction).

 

    	26

     

    

 

(vii) Compliance
with Laws. The Company shall have complied with all applicable federal, state and local governmental laws, rules,
regulations and ordinances in connection with the execution, delivery and performance of this Agreement and the other Transaction
Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby.

 

(viii) No
Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated,
threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which
would materially modify or delay any of the transactions contemplated by the Transaction Documents.

 

(ix) No
Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority shall
have been commenced, and no inquiry or investigation by any governmental authority shall have been commenced, against the Company or
any Subsidiary, or any of the officers, directors or Affiliates of the Company or any Subsidiary, that could reasonably be expected
to restrain, prevent or change the transactions contemplated by the Transaction Documents.

 

(x) Listing
of Shares. All of the Shares that have been and may be issued pursuant to this Agreement shall have been approved for
listing or quotation on the Trading Market as of the Commencement Date, subject only to notice of issuance.

 

(xi) No
Bankruptcy Proceedings. No Person shall have commenced a proceeding against the Company pursuant to any Bankruptcy Law. The
Company shall not have, pursuant to or within the meaning of any Bankruptcy Law, (a) commenced a voluntary case, (b) consented to
the entry of an order for relief against it in an involuntary case, (c) consented to the appointment of a Custodian of the Company
or for all or substantially all of its property, or (d) made a general assignment for the benefit of its creditors. A court of
competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (I) is for relief against the Company
in an involuntary case, (II) appoints a Custodian of the Company or for all or substantially all of its property, or (III) orders
the liquidation of the Company or any of its Subsidiaries.

 

    	27

     

    

 

(xii)
Delivery of Commencement Irrevocable Transfer Agent Instructions and Notice of Effectiveness. To the extent required by
the Transfer Agent: (x) the Commencement Irrevocable Transfer Agent Instructions shall have been executed by the Company and delivered
to and acknowledged in writing by the Company’s transfer agent, and (y) the Notice of Effectiveness relating to the Initial Registration
Statement shall have been executed by the Company’s outside counsel and delivered to the Transfer Agent, in each case directing
the Transfer Agent to issue to the Investor or its designated Broker-Dealer all of the Shares included in the Initial Registration Statement
as DWAC Shares in accordance with this Agreement and the Registration Rights Agreement.

 

(xiii)
Reservation of Shares. As of the Commencement Date, the Company shall have reserved out of its authorized and unissued
Common Stock a number of shares of Common Stock equal to the Exchange Cap solely for the purpose of effecting Purchases under this Agreement.

 

(xiv)
Opinions of Company Counsel. On the Commencement Date, the Investor shall have received the opinions and negative assurances
from outside counsel to the Company, dated the Commencement Date, in the forms mutually agreed to by the Company and the Investor prior
to the Execution Date.

 

(xv)
Comfort Letter. On the Commencement Date, the Investor shall have received from the independent registered chartered professional
accountants for the Company, a letter dated the Commencement Date addressed to the Investor, in customary form with respect to the audited
and unaudited financial statements and certain financial information contained in the Registration Statement and the Prospectus, and
any Prospectus Supplement, except that the specific date referred to therein for the carrying out of procedures shall be no more than
three Business Days prior to the Commencement Date.

 

Section
7.3 Conditions Precedent to Purchases after Commencement Date. The right of the Company to deliver Purchase Notices
under this Agreement after the Commencement Date, and the obligation of the Investor to accept Purchase Notices under this Agreement
after the Commencement Date, are subject to the satisfaction of each of the conditions set forth in this Section 7.3 at the applicable
Purchase Commencement Time for the Purchase to be effected pursuant to the applicable Purchase Notice timely delivered by the Company
to the Investor in accordance with this Agreement (each such time, a “Purchase Condition Satisfaction Time”).

 

(i)
Satisfaction of Certain Prior Conditions. Each of the conditions set forth in subsections (i), (ii), and (vii) through
(xiii) set forth in Section 7.2 shall be satisfied at the applicable Purchase Condition Satisfaction Time after the Commencement
Date (with the terms “Commencement” and “Commencement Date” in the conditions set forth in subsections (i) and
(ii) of Section 7.2 replaced with “applicable Purchase Condition Satisfaction Time”); provided, however,
that the Company shall not be required to deliver the Compliance Certificate after the Commencement Date, except as provided in Section
6.15 and Section 7.3(v).

 

    	28

     

    

 

(ii)
Initial Registration Statement Effective. The Initial Registration Statement covering the resale by the Investor of the
Registrable Securities included therein filed by the Company with the Commission pursuant to Section 2(a) of the Registration Rights
Agreement, and any post-effective amendment thereto required to be filed by the Company with the Commission after the Commencement Date
and prior to the applicable Purchase Notice Date pursuant to the Registration Rights Agreement, in each case shall have been declared
effective under the Securities Act by the Commission and shall remain effective for the applicable Registration Period (as defined in
the Registration Rights Agreement), and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement
thereto, to resell all of the Shares included in the Initial Registration Statement, and any post-effective amendment thereto, that have
been issued and sold to the Investor hereunder pursuant to all Purchase Notices delivered by the Company to the Investor prior to such
applicable Purchase Notice Date and (c) all of the Shares included in the Initial Registration Statement, and any post-effective amendment
thereto, that are issuable pursuant to the applicable Purchase Notice delivered by the Company to the Investor with respect to a Purchase
to be effected hereunder on such applicable Purchase Notice Date.

 

(iii)
Any Required New Registration Statement Effective. Any New Registration Statement covering the resale by the Investor of
the Registrable Securities included therein, and any post-effective amendment thereto, required to be filed by the Company with the Commission
pursuant to the Registration Rights Agreement after the Commencement Date and prior to the applicable Purchase Notice Date, in each case
shall have been declared effective under the Securities Act by the Commission and shall remain effective for the applicable Registration
Period, and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement thereto, to resell (a) all
of the Shares included in such New Registration Statement, and any post-effective amendment thereto, that have been issued and sold to
the Investor hereunder pursuant to all Purchase Notices delivered by the Company to the Investor prior to such applicable Purchase Notice
Date and (b) all of the Shares included in such new Registration Statement, and any post-effective amendment thereto, that are issuable
pursuant to the applicable Purchase Notice delivered by the Company to the Investor with respect to a Purchase to be effected hereunder
on such applicable Purchase Notice Date.

 

(iv)
Delivery of Subsequent Irrevocable Transfer Agent Instructions and Notice of Effectiveness. With respect to any post-effective
amendment to the Initial Registration Statement, any New Registration Statement or any post-effective amendment to any New Registration
Statement, in each case declared effective by the Commission after the Commencement Date, the Company shall have delivered or caused
to be delivered to the Transfer Agent (a) irrevocable instructions in the form substantially similar to the Commencement Irrevocable
Transfer Agent Instructions executed by the Company and acknowledged in writing by the Transfer Agent and (b) the Notice of Effectiveness,
in each case modified as necessary to refer to such Registration Statement or post-effective amendment and the Registrable Securities
included therein, to issue the Registrable Securities included therein as DWAC Shares in accordance with the terms of this Agreement
and the Registration Rights Agreement.

 

    	29

     

    

 

(v)
No Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by
the Commission or any other federal or state governmental authority for any additional information relating to the Initial Registration
Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Registration
Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto, in each case to which the Company shall not have responded to
the satisfaction of the Commission or such other authority; (b) the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of the Initial Registration Statement or any post-effective amendment thereto,
any New Registration Statement or any post-effective amendment thereto, or prohibiting or suspending the use of the Prospectus contained
in any of the foregoing or any Prospectus Supplement thereto or of the suspension of qualification or exemption from qualification of
the Shares for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose;
or (c) the occurrence of any event or the existence of any condition or state of facts, which makes any statement of a material fact
made in the Initial Registration Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective
amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto untrue or which requires
the making of any additions to or changes to the statements then made in the Initial Registration Statement or any post-effective amendment
thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing
or any Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary
in order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in the light of the circumstances
under which they were made) not misleading, or which requires an amendment to the Initial Registration Statement or any post-effective
amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the
foregoing or any Prospectus Supplement thereto to comply with the Securities Act or any other law (other than the transactions contemplated
by the applicable Purchase Notice delivered by the Company to the Investor with respect to a Purchase to be effected hereunder on such
applicable Purchase Notice Date and the settlement thereof), in each case which additions, changes, amendments or supplements shall not
have been made. The Company shall have no Knowledge of any event that could reasonably be expected to have the effect of causing the
suspension of the effectiveness of the Initial Registration Statement or any post-effective amendment thereto, any New Registration Statement
or any post-effective amendment thereto, or the prohibition or suspension of the use of the Prospectus contained in any of the foregoing
or any Prospectus Supplement thereto in connection with the resale of the Registrable Securities by the Investor.

 

    	30

     

    

 

(vi)
Other Commission Filings. The final Prospectus included in any post-effective amendment to the Initial Registration Statement,
and any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 2.3 and the
Registration Rights Agreement after the Commencement Date and prior to the applicable Purchase Notice Date, shall have been filed with
the Commission in accordance with Section 2.3 and the Registration Rights Agreement. The final Prospectus included in any New
Registration Statement and in any post-effective amendment thereto, and any Prospectus Supplement thereto, required to be filed by the
Company with the Commission pursuant to Section 2.3 and the Registration Rights Agreement after the Commencement Date and prior
to the applicable Purchase Notice Date, shall have been filed with the Commission in accordance with Section 2.3 and the Registration
Rights Agreement. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed
by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required to have
been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, after the Commencement Date and prior to the applicable Purchase Notice
Date, shall have been filed with the Commission.

 

(vii)
No Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended
by the Commission, the Trading Market or FINRA (except for any suspension of trading of limited duration agreed to by the Company, which
suspension shall be terminated prior to the applicable Purchase Notice Date), the Company shall not have received any final and non-appealable
notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain (unless, prior to
such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect
to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the effect that a suspension of, or
restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the
Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall have notified the Company
in writing that DTC has determined not to impose any such suspension or restriction).

 

(viii)
Certain Limitations. The issuance and sale of the Shares issuable pursuant to the applicable Purchase Notice shall not
(a) exceed the applicable Purchase Notice Limit, (b) cause the Beneficial Ownership Limitation to be exceeded, or (c) cause the Exchange
Cap (to the extent applicable under Section 3.3) to be exceeded, unless, in the case of this clause (c), the Company’s stockholders
have theretofore approved the issuance of Common Stock under this Agreement in excess of the Exchange Cap in accordance with the applicable
rules of the Trading Market.

 

(ix)
Shares Authorized and Delivered. All of the Shares issuable pursuant to the applicable Purchase Notice shall have been
duly authorized by all necessary corporate action of the Company. All Shares relating to all prior Purchase Notices required to have
been received by the Investor as DWAC Shares under this Agreement prior to the applicable Purchase Condition Satisfaction Time for the
applicable Purchase shall have been delivered to the Investor as DWAC Shares in accordance with this Agreement.

 

(x)
Bring-Down Opinions of Company Counsel, Bring-Down Comfort Letters and Compliance Certificates. The Investor shall have
received (a) all Bring-Down Opinions from outside counsel to the Company for which the Company was obligated to instruct its outside
counsel to deliver to the Investor prior to the applicable Purchase Condition Satisfaction Time for the applicable Purchase, (b) all
bring-down comfort letters provided by the Company’s auditors and delivered to the Investor prior to the applicable Purchase Condition
Satisfaction Time for the applicable Purchase and (c) all Compliance Certificates from the Company that the Company was obligated to
deliver to the Investor prior to the applicable Purchase Condition Satisfaction Time for the applicable Purchase, in each case in accordance
with Section 6.15.

 

    	31

     

    

 

Article
VIII

TERMINATION

 

Section
8.1 Automatic Termination. Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically
on the earliest to occur of (i) the two year anniversary of the Commencement Date, (ii) the date on which the Investor shall have purchased
the Total Commitment worth of Shares pursuant to this Agreement, (iii) the date on which the Common Stock shall have failed to be listed
or quoted on the Trading Market or any other Eligible Market, (iv) the thirtieth (30th) Trading Day next following the date on which,
pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, in each case that is not discharged or dismissed prior to such thirtieth (30th) Trading Day, (v) the date on which
the Merger Agreement is terminated, if terminated prior to completion of the Merger, and (vi) the date on which, pursuant to or within
the meaning of any Bankruptcy Law, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company
makes a general assignment for the benefit of its creditors.

 

Section
8.2 Other Termination. Subject to Section 8.3, the Company may terminate this Agreement after the Commencement Date
effective upon three (3) Trading Days’ prior written notice to the Investor in accordance with Section 10.4; provided, however,
that (i) the Company shall have paid the Commitment Shares to the Investor required to be paid pursuant to Section 10.1(ii) of
this Agreement prior to such termination, and (ii) prior to issuing any press release, or making any public statement or announcement,
with respect to such termination, the Company shall consult with the Investor and its counsel on the form and substance of such press
release or other disclosure. Subject to Section 8.3, this Agreement may be terminated at any time by the mutual written consent
of the parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent. Subject to
Section 8.3, the Investor shall have the right to terminate this Agreement effective upon three (3) Trading Days’ prior
written notice to the Company in accordance with Section 10.4, if: (a) a Fundamental Transaction shall have occurred; (b) the
Company is in breach or default in any material respect of any of its covenants and agreements the Registration Rights Agreement, and,
if such breach or default is capable of being cured, such breach or default is not cured within 60 Trading Days after notice of such
breach or default is delivered to the Company pursuant to Section 10.4 of this Agreement; (c) while a Registration Statement,
or any post-effective amendment thereto, is required to be maintained effective pursuant to the terms of the Registration Rights Agreement
and the Investor holds any Registrable Securities, the effectiveness of such Registration Statement, or any post-effective amendment
thereto, lapses for any reason (including, without limitation, the issuance of a stop order by the Commission) or such Registration Statement
or any post-effective amendment thereto, the Prospectus contained therein or any Prospectus Supplement thereto otherwise becomes unavailable
to the Investor for the resale of all of the Registrable Securities included therein in accordance with the terms of the Registration
Rights Agreement, and such lapse or unavailability continues for a period of 45 consecutive Trading Days or for more than an aggregate
of 90 Trading Days in any 365-day period, other than due to acts of the Investor; (d) trading in the Common Stock on the Trading Market
(or if the Common Stock is then listed on an Eligible Market, trading in the Common Stock on such Eligible Market) shall have been suspended
and such suspension continues for a period of five (5) consecutive Trading Days; or (e) the Company is in material breach or default
of any of its covenants and agreements contained in this Agreement, and, if such breach or default is capable of being cured, such breach
or default is not cured within 20 Trading Days after notice of such breach or default is delivered to the Company pursuant to Section
10.4 of this Agreement. Unless notification thereof is required elsewhere in this Agreement (in which case such notification shall be
provided in accordance with such other provision), the Company shall promptly (but in no event later than 24 hours) notify the Investor
(and, if required under applicable law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable
rules and regulations of the Trading Market (or if the Common Stock is then listed on an Eligible Market, under the applicable rules
and regulations of such Eligible Market), the Company shall publicly disclose such information in accordance with Regulation FD and the
applicable rules and regulations of the Trading Market (or such Eligible Market, as applicable)) upon becoming aware of any of the events
set forth in the immediately preceding sentence.

 

Section
8.3 Effect of Termination. In the event of termination by the Company or the Investor (other than by mutual termination)
pursuant to Section 8.2, written notice thereof shall forthwith be given to the other party as provided in Section
10.4 and the transactions contemplated by this Agreement shall be terminated without further action by either party. If this
Agreement is terminated as provided in Section 8.1 or Section 8.2, this Agreement shall become void and of no further
force and effect, except that (i) the provisions of Article V (Representations, Warranties and Covenants of the
Company), Article IX (Indemnification), Article X (Miscellaneous) and this Article VIII (Termination) shall
remain in full force and effect indefinitely notwithstanding such termination, and, (ii) so long as the Investor owns any
Shares, the covenants and agreements of the Company contained in Article VI (Additional Covenants) shall remain in full force
and notwithstanding such termination for a period of thirty (30) days following such termination. Notwithstanding anything in this
Agreement to the contrary, no termination of this Agreement by any party shall (i) become effective prior to the second
(2nd) Trading Day immediately following the Valuation Period for the applicable Purchase Notice (it being hereby
acknowledged and agreed that no termination of this Agreement shall limit, alter, modify, change or otherwise affect any of the
Company’s or the Investor’s rights or obligations under the Transaction Documents with respect to any pending Purchase
that has not fully settled, and that the parties shall fully perform their respective obligations with respect to any such pending
Purchase under the Transaction Documents), (ii) limit, alter, modify, change or otherwise affect the Company’s or the
Investor’s rights or obligations under the Registration Rights Agreement, all of which shall survive any such termination, or
(iii) affect the Commitment Shares payable to the Investor pursuant to Section 10.1(ii), it being hereby acknowledged
and agreed that the entire amount of the Commitment Shares shall be fully earned by the Investor and shall be non-refundable as of
the effective date of the Merger, regardless of whether any Purchases are made or settled hereunder or any subsequent termination of
this Agreement. Nothing in this Section 8.3 shall be deemed to release the Company or the Investor from any liability
for any breach or default under this Agreement, the Registration Rights Agreement or any of the other Transaction Documents to which
it is a party, or to impair the rights of the Company and the Investor to compel specific performance by the other party of its
obligations under this Agreement, the Registration Rights Agreement or any of the other Transaction Documents to which it is a
party.

 

    	32

     

    

 

Article
IX

INDEMNIFICATION

 

Section
9.1 Indemnification. In Subject to the provisions of this Section 9.1 and Section 9.2, the each party (an “Indemnifying
Party”) shall indemnify and hold harmless the other party and each of its directors, officers, shareholders, members, partners,
employees, representatives and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
the lack of such title or any other title), each Person, if any, who controls the Investor (within the meaning of Section 15 of the Securities
Act or Section 20(a) of the Exchange Act), and the respective directors, officers, shareholders, members, partners, employees, attorneys,
representatives and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
the lack of such title or any other title) of such controlling Persons (each, an “Indemnified Party”), from
and against all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses (including all judgments, amounts
paid in settlement, court costs, reasonable attorneys’ fees and costs of defense and investigation, but excluding any consequential,
special, punitive or indirect damages, except to the extent payable to a third party) (collectively, “Damages”)
that any Indemnified Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties,
covenants or agreements made by the Indemnifying Party in this Agreement or in the other Transaction Documents to which it is a party,
or (b) any action, suit, claim or proceeding (including for these purposes a derivative action brought on behalf of the Indemnifying
Party) instituted against such Indemnified Party arising out of or resulting from the execution, delivery, performance or enforcement
of the Transaction Documents, other than claims for indemnification within the scope of Section 6 of the Registration Rights Agreement;
provided, however, that (x) the foregoing indemnity shall not apply to any Damages to the extent, but only to the extent, that such Damages
resulted from a breach of any of the Indemnified Party’s representations, warranties, covenants or agreements contained in this
Agreement or the Registration Rights Agreement, (y) the Indemnifying Party shall not be liable under subsection (b) of this Section
9.1 to the extent, but only to the extent, that a court of competent jurisdiction shall have determined by a final judgment (from
which no further appeals are available) that such Damages resulted from any acts or failures to act, undertaken or omitted to be taken
by such Indemnified Party through its fraud, bad faith, gross negligence, or willful or reckless misconduct; and (z) the maximum aggregate
amount of the Company’s indemnification obligations hereunder shall be the aggregate Purchase Amounts actually paid to the Company
by the Investor pursuant to this Agreement, and the maximum aggregate amount of the Investor’s indemnification obligations hereunder
shall be $500,000.

 

The
Indemnifying Party shall reimburse any Indemnified Party promptly upon demand (with accompanying presentation of documentary evidence)
for all legal and other costs and expenses reasonably incurred by such Indemnified Party in connection with (i) any action, suit, claim
or proceeding, whether at law or in equity, to enforce compliance by the Indemnifying Party with any provision of the Transaction Documents
or (ii) any other any action, suit, claim or proceeding, whether at law or in equity, with respect to which it is entitled to indemnification
under this Section 9.1; provided that the Indemnified shall promptly reimburse the Indemnifying Party for all such legal
and other costs and expenses to the extent a court of competent jurisdiction determines that any Indemnified Party was not entitled to
such reimbursement.

 

To
the extent that the foregoing undertakings by the Indemnifying Party set forth in this Section 9.1 may be unenforceable for any
reason, the Indemnifying Party shall make the maximum contribution to the payment and satisfaction of each of the Damages which is permissible
under applicable law.

 

    	33

     

    

 

Section
9.2 Indemnification Procedures. Promptly after an Indemnified Party receives notice of a claim or the commencement
of an action for which the Indemnified Party intends to seek indemnification under Section 9.1, the Indemnified Party will notify
the Indemnifying Party in writing of the claim or commencement of the action, suit or proceeding; provided, however, that failure
to notify the Indemnifying Party will not relieve the Indemnifying Party from liability under Section 9.1, except to the extent
it has been materially prejudiced by the failure to give notice. The Indemnifying Party will be entitled to participate in the defense
of any claim, action, suit or proceeding as to which indemnification is being sought, and if the Indemnifying Party acknowledges in writing
the obligation to indemnify the Indemnified Party against whom the claim or action is brought, the Indemnifying Party may (but will not
be required to) assume the defense against the claim, action, suit or proceeding with counsel satisfactory to it. After the Indemnifying
Party notifies the Indemnified Party that the Indemnifying Party wishes to assume the defense of a claim, action, suit or proceeding,
the Indemnifying Party will not be liable for any further legal or other expenses incurred by the Indemnified Party in connection with
the defense against the claim, action, suit or proceeding except that if, in the opinion of counsel to the Indemnified Party, it would
be inappropriate under the applicable rules of professional responsibility for the same counsel to represent both the Indemnifying Party
and such Indemnified Party. In such event, the Indemnifying Party will pay the reasonable fees and expenses of no more than one separate
counsel for all such Indemnified Parties promptly as such fees and expenses are incurred. Each Indemnified Party, as a condition to receiving
indemnification as provided in Section 9.1, will cooperate in all reasonable respects with the Indemnifying Party in the defense
of any action or claim as to which indemnification is sought. The Indemnifying Party will not be liable for any settlement of any action
effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. The Indemnifying
Party will not, without the prior written consent of the Indemnified Party, effect any settlement of a pending or threatened action with
respect to which an Indemnified Party is, or is informed that it may be, made a party and for which it would be entitled to indemnification,
unless the settlement includes an unconditional release of the Indemnified Party from all liability and claims which are the subject
matter of the pending or threatened action.

 

The
remedies provided for in this Article X are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any Indemnified Party at law or in equity.

 

Article
X

MISCELLANEOUS

 

Section
10.1 Certain Fees and Expenses; Commitment Shares; Commencement Irrevocable Transfer Agent Instructions.

 

(i)
Certain Fees and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by this Agreement.
The Company shall pay all U.S. federal, state and local stamp and other similar transfer and other taxes and duties levied in connection
with issuance of the Shares pursuant hereto.

 

    	34

     

    

 

(ii)
Commitment Shares. In consideration for the Investor’s execution and delivery of this Agreement, the Company shall issue
the Commitment Shares to the Investor or its designee (in which case such designee name shall have been provided by the Investor to the
Company in writing prior to the Closing Date) on the Commitment Shares Determination Date, which issuance shall be evidenced by one or
more book-entry statement(s) reflecting the Commitment Shares in the name of the Investor or its designee. Such book-entry statement(s)
shall be delivered to the Investor by overnight courier at its address set forth in Section 10.4. For the avoidance of doubt,
all of the Commitment Shares shall be fully earned by the Investor and shall be non-refundable as of the Closing Date, regardless of
whether any Purchases are made or settled hereunder or any subsequent termination of this Agreement. Upon issuance pursuant to this Section
10.1(ii), the Commitment Shares shall constitute “restricted securities” as such term is defined in Rule 144(a)(3) under
the Securities Act and, subject to the provisions of Section 10.1(iii), the book-entry statement(s) reflecting the Commitment
Shares shall bear the restrictive legend set forth below in Section 10.1(iii). The Commitment Shares shall constitute Registrable
Securities and shall be included in the Initial Registration Statement and any post-effective amendment thereto, and the Prospectus included
therein, and, if necessary to register the resale thereof by the Investor under the Securities Act, in any New Registration Statement
and any post-effective amendment thereto, and the Prospectus included therein, in each case in accordance with this Agreement and the
Registration Rights Agreement.

 

(iii)
Irrevocable Transfer Agent Instructions; Notice of Effectiveness. On the Effective Date of the Initial Registration Statement
and prior to Commencement, the Company shall deliver or cause to be delivered to its Transfer Agent (and thereafter, shall deliver or
cause to be delivered to any subsequent transfer agent of the Company), (i) irrevocable instructions executed by the Company and acknowledged
in writing by the Company’s transfer agent (the “Commencement Irrevocable Transfer Agent Instructions”)
and (ii) the notice of effectiveness in the form attached as an exhibit to the Registration Rights Agreement (the “Notice
of Effectiveness”) relating to the Initial Registration Statement executed by the Company’s outside counsel, in each
case directing the Transfer Agent to issue to the Investor or its designated Broker-Dealer at which the account or accounts to be credited
with the Shares being purchased by Investor are maintained any Registrable Securities included in the Initial Registration Statement
as DWAC Shares, if and when such Registrable Securities are issued in accordance with this Agreement and the Registration Rights Agreement.
With respect to any post-effective amendment to the Initial Registration Statement, any New Registration Statement or any post-effective
amendment to any New Registration Statement, in each case declared effective by the Commission after the Commencement Date, the Company
shall deliver or cause to be delivered to its Transfer Agent (and thereafter, shall deliver or cause to be delivered to any subsequent
transfer agent of the Company) (i) irrevocable instructions in the form substantially similar to the Commencement Irrevocable Transfer
Agent Instructions executed by the Company and acknowledged in writing by the Transfer Agent and (ii) the Notice of Effectiveness, in
each case modified as necessary to refer to such Registration Statement or post-effective amendment and the Registrable Securities included
therein, to issue the Registrable Securities included therein as DWAC Shares in accordance with the terms of this Agreement and the Registration
Rights Agreement. For the avoidance of doubt, all Shares to be issued in respect of any Purchase Notice delivered to the Investor pursuant
to this Agreement shall be issued to the Investor in accordance with Section 3.2 by crediting the Investor’s account at
DTC as DWAC Shares, and the Company shall not take any action or give instructions to any transfer agent of the Company otherwise. The
Company represents and warrants to the Investor that, while this Agreement is effective, no instruction other than those referred to
in this Section 10.1(iii) will be given by the Company to its Transfer Agent, or any successor transfer agent of the Company,
with respect to the Shares from and after Commencement, and the Registrable Securities covered by the Initial Registration Statement
or any post-effective amendment thereof, or any New Registration Statement or post-effective amendment thereof, as applicable, shall
otherwise be freely transferable on the books and records of the Company and no stop transfer instructions shall be maintained against
the transfer thereof. The Company agrees that if the Company fails to fully comply with the provisions of this Section 10.1(iii)
within three (3) Trading Days after the date on which the Investor has provided any deliverables that the Investor may be required to
provide to the Company or its Transfer Agent (if any), the Company shall, at the Investor’s written instruction delivered after
such third Trading Day and prior to the time on which the Company subsequently fully complies with the provisions of this Section
10.1(iii), purchase from the Investor all shares of Common Stock purchased or acquired by the Investor pursuant to this Agreement
that contain any restrictive legend or that have any stop transfer orders maintained that prohibit or impede the transfer thereof in
any respect at the greater of (i) 115% of the purchase price paid by the Investor for such shares of Common Stock (as applicable) and
(ii) the Closing Sale Price of the Common Stock on the date of the Investor’s written instruction.

 

    	35

     

    

 

Section
10.2 Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial.

 

(i)
The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either
party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other
party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond
or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.

 

(ii)
Each of the Company and the Investor (a) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts of
the United States sitting in the State of California for the purposes of any suit, action or proceeding arising out of or relating to
this Agreement, and (b) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue
of the suit, action or proceeding is improper. Each of the Company and the Investor consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 10.2 shall
affect or limit any right to serve process in any other manner permitted by law.

 

    	36

     

    

 

(iii)
EACH OF THE COMPANY AND THE INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK
TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN TO ENTER INTO THIS AGREEMENT BY,
AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS Section 10.2.

 

Section
10.3 Entire Agreement. The Transaction Documents set forth the entire agreement and understanding of the parties with respect
to the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties,
both oral and written, with respect to such matters. There are no promises, undertakings, representations or warranties by either party
relative to subject matter hereof not expressly set forth in the Transaction Documents. All exhibits to this Agreement are hereby incorporated
by reference in, and made a part of, this Agreement as if set forth in full herein.

 

Section
10.4 Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder
shall be in writing and shall be effective (a) upon hand delivery or electronic mail delivery at the address or number designated below
(if delivered on a business day during normal business hours where such notice is to be received), or the first business day following
such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on
the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual
receipt of such mailing, whichever shall first occur. The address for such communications shall be:

 

If
to the Company:

 

Aesther
Healthcare Acquisition Corporation

515 Madison Avenue

Suite 8078

New York, NY 10022

Telephone Number: (646) 908-2658

Email:
suren@aestherhealthcarespac.com

Attention: Suren Ajjarapu

 

If
to the Investor:

 

White
Lion Capital, LLC

17631 Ventura Blvd., Suite 1008

Encino, CA 91316

Telephone Number: (818) 217-1706

Email:
team@whitelioncapital.com

 

    	37

     

    

 

With
a copy (which shall not constitute notice) to:

 

Greenburg
Traurig, P.A.

333 S.E. 2nd Avenue

Miami, FL 33131

Email:
owensjohn@gtlaw.com

Attention: John D. Owens III, Esq.

 

Either
party hereto may from time to time change its address for notices by giving at least five (5) days’ advance written notice of such
changed address to the other party hereto.

 

Section
10.5 Waivers. No provision of this Agreement may be waived by the parties from and after the date that is one (1) Trading
Day immediately preceding the filing of the Initial Registration Statement with the Commission. Subject to the immediately preceding
sentence, no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercises thereof or of any
other right, power or privilege.

 

Section
10.6 Amendments. No provision of this Agreement may be amended by the parties from and after the date that is one (1) Trading
Day immediately preceding the filing of the Initial Registration Statement with the Commission. Subject to the immediately preceding
sentence, no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto.

 

Section
10.7 Headings. The article, section and subsection headings in this Agreement are for convenience only and shall not constitute
a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context
clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms
thereof. The terms “including,” “includes,” “include” and words of like import shall be construed
broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof”
and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

Section
10.8 Construction. The parties agree that each of them and their respective counsel has reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents. In addition, each and every reference
to share prices (including the Floor Price) and number of shares of Common Stock in any Transaction Document shall, in all cases, be
subject to adjustment for any stock splits, stock combinations, stock dividends, recapitalizations, reorganizations and other similar
transactions that occur on or after the Execution Date. Any reference in this Agreement to “Dollars” or “$” shall
mean the lawful currency of the United States of America. Any references to “Section” or “Article” in this Agreement
shall, unless otherwise expressly stated herein, refer to the applicable Section or Article of this Agreement.

 

    	38

     

    

 

Section
10.9 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors. Neither the Company nor the Investor may assign this Agreement or any of their respective rights or obligations hereunder
to any Person.

 

Section
10.10 No Third Party Beneficiaries. Except as expressly provided in Article IX, this Agreement is intended only for
the benefit of the parties hereto and their respective successors, and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.

 

Section
10.11 Governing Law. This Agreement shall be governed by and construed in accordance with the internal procedural and substantive
laws of the State of New York, without giving effect to the choice of law provisions of such state that would cause the application of
the laws of any other jurisdiction.

 

Section
10.12 Survival. The representations, warranties, covenants and agreements of the Company and the Investor contained in this
Agreement shall survive the execution and delivery hereof until the termination of this Agreement; provided, however, that (i) the provisions
of Article VIII (Termination), Article IX (Indemnification) and this Article X (Miscellaneous) shall remain in full
force and effect indefinitely for the longest period allowed under applicable laws notwithstanding such termination, and, (ii) so long
as the Investor owns any Shares, the covenants and agreements of the Company and the Investor contained in Article VI (Additional
Covenants), shall remain in full force and effect notwithstanding such termination for a period of thirty (30) days following such termination.

 

Section
10.13 Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party;
provided that a facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

Section
10.14 Publicity. The Company shall afford the Investor and its counsel with a reasonable opportunity to review and comment
upon, shall consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all such comments
from the Investor or its counsel on, any press release, Commission filing or any other public disclosure made by or on behalf of the
Company relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated
thereby, prior to the issuance, filing or public disclosure thereof. For the avoidance of doubt, the Company shall not be required to
submit for review any such disclosure (i) contained in periodic reports filed with the Commission under the Exchange Act if it shall
have previously provided the same disclosure to the Investor or its counsel for review in connection with a previous filing or (ii) any
Prospectus Supplement if it contains disclosure that does not reference the Investor, its purchases hereunder or any aspect of the Transaction
Documents or the transactions contemplated thereby.

 

    	39

     

    

 

Section
10.15 Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction
shall determine that any one or more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other
provision or part of a provision of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal
or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal
and enforceable to the maximum extent possible.

 

Section
10.16 Further Assurances. From and after the Closing Date, upon the request of the Investor or the Company, each of
the Company and the Investor shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or
desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

Section
10.17 Waiver of Claims Against Trust. Reference is made to the prospectus of the Company, dated as of September 14, 2021,
and filed with the Commission on September 16, 2021 (File No. 333-258012) (the “IPO Prospectus”). The Investor
hereby represents and warrants that it has read the IPO Prospectus and understands that the Company has established a trust account with
the proceeds from its initial public offering pursuant to that certain Investment Management Trust Agreement, dated as of September 14,
2021, as it may be amended, by and between the Company and Continental Stock Transfer & Trust Company, in its capacity as trustee,
as well as any other agreements entered into related to or governing such trust account (the “Trust Account”)
in accordance with the IPO Prospectus containing the proceeds of the IPO and the overallotment shares acquired by the Company’s
underwriters and from certain private placements occurring simultaneously with the IPO (including interest accrued from time to time
thereon) for the benefit of the Company’s public stockholders (including overallotment shares acquired by the Company’s underwriters)
(the “Public Stockholders”) and that, except as otherwise described in the IPO Prospectus, the Company may
disburse monies from the Trust Account only: (a) to the Public Stockholders in the event they elect to redeem their shares of Common
Stock in connection with the consummation of its initial business combination (as such term is used in the IPO Prospectus) (“Business
Combination”) or in connection with an amendment to the Company’s certificate of incorporation and bylaws, in each
case as amended (the “Organizational Documents”), to extend the Company’s deadline to consummate a Business
Combination, (b) to the Public Stockholders if the Company fails to consummate a Business Combination within 18 months after the closing
of the IPO, subject to extension by amendment to the Organizational Documents, (c) with respect to any interest earned on the amounts
held in the Trust Account, amounts necessary to pay for any taxes, and (d) to the Company after or concurrently with the consummation
of a Business Combination. For and in consideration of the Company entering into this Agreement and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Investor hereby agrees on behalf of itself and its Affiliates that,
notwithstanding anything to the contrary in this Agreement, none of the Investor nor any of its Affiliates do now or shall at any time
hereafter have any right, title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or
make any claim against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result
of, in connection with or relating in any way to, this Agreement or any proposed or actual business relationship between the Company
or any of its Representatives, on the one hand, and the Investor or any of its Representatives, on the other hand, or any other matter,
and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal liability (collectively, the
“Released Claims”). The Investor on behalf of itself and its Affiliates hereby irrevocably waives any Released
Claims that it or any of its Affiliates may have against the Trust Account (including any distributions therefrom) now or in the future
as a result of, or arising out of, any negotiations, contracts or agreements with the Company or its Representatives and will not seek
recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach
of this Agreement or any other agreement with the Company or its Affiliates). The Investor agrees and acknowledges that such irrevocable
waiver is material to this Agreement and specifically relied upon by the Company and its Affiliates to induce the Company to enter in
this Agreement, and the Investor further intends and understands such waiver to be valid, binding and enforceable against it and each
of its Affiliates under applicable Law. To the extent that the Investor or any of its Affiliates commences any claim, demand, charge,
action, suit, litigation, audit, settlement, complaint, stipulation, assessment or arbitration, or any request (including any request
for information), inquiry, hearing, proceeding or investigation (each, an “Action”) based upon, in connection
with, relating to or arising out of any matter relating to the Company or its Representatives, which proceeding seeks, in whole or in
part, monetary relief against the Company or its Representatives, the Investor hereby acknowledges and agrees that its and its Affiliates’
sole remedy shall be against funds held outside of the Trust Account and that such claim shall not permit it or any of its Affiliates
(or any Person claiming on any of their behalfs or in lieu of them) to have any claim against the Trust Account (including any distributions
therefrom) or any amounts contained therein. In the event that the Investor or any of its Affiliates commences Action based upon, in
connection with, relating to or arising out of any matter relating to the Company or its representatives which proceeding seeks, in whole
or in part, relief against the Trust Account (including any distributions therefrom) or the Public Stockholders, whether in the form
of money damages or injunctive relief, the Company and its representatives, as applicable, shall be entitled to recover from the Investor
and its Affiliates, as applicable, the associated legal fees and costs in connection with any such Action, in the event the Company or
its representatives, as applicable, prevails in such Action. This Section 10.17 shall survive termination of this Agreement for any reason
and continue indefinitely.

 

[Signature
Pages Follow]

 

    	40

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officer as of the Execution
Date.

 

	 	Aesther
    Healthcare Acquisition Corporation:
	 	 
	 	By:	 
	 	 	 
	 	Name:	Suren
    Ajjarapu
	 	Title:	Chief
    Executive Officer
	 	 
	 	WHITE
    LION CAPITAL, LLC:
	 	 
	 	By:	 
	 	 	 
	 	Name:	Yash
    Thukral
	 	Title:	Managing
    Member

 

    	41

     

    

 

ANNEX
I TO THE

 

COMMON
STOCK PURCHASE AGREEMENT

 

DEFINITIONS

 

“Adjusted
Purchase Notice Share Amount” shall equal the product of (a) the total applicable number of Purchase Notice Shares in such
applicable Purchase Notice and (b) the quotient obtained by dividing (i) the number of hours commencing at the start of the Valuation
Period and ending at the time of the trade at or below the Threshold Price (rounded up to the nearest whole hour, subject to a maximum
of 13 hours) by (ii) 13. For example, if the Common Stock trades below the Threshold Price on the second day of the Valuation Period
at 1:01 p.m. New York time, the number of hours used in the Adjusted Purchase Notice Share Amount calculation shall be 11 hours.

 

Adjusted Purchase Notice Share Amount =a × i/13

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control
with a Person, as such terms are used in and construed under Rule 144.

 

“Agreement”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Average
Daily Trading Volume” shall mean the median daily trading volume of the Company’s Common Stock over the most recent
five (5) Trading Days prior to the respective Purchase Notice Date, as reported by Bloomberg.

 

“Average
Price” means a price per Share (rounded to the nearest tenth of a cent) equal to the quotient obtained by dividing (i)
the aggregate gross purchase price paid by the Investor for all Shares purchased pursuant to this Agreement, by (ii) the aggregate number
of Shares issued pursuant to this Agreement.

 

“Bankruptcy
Law” means Title 11, U.S. Code, or any similar U.S. federal or state law for the relief of debtors.

 

“Base
Price” means a price per Share equal to the sum of (i) the Minimum Price and (ii) $0.02 (subject to adjustment for any
reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that occurs on or
after the date of this Agreement).

 

“Beneficial
Ownership Limitation” shall have the meaning assigned to such term in Section 3.4.

 

“Bloomberg”
means Bloomberg, L.P.

 

“Bring-Down
Opinion” shall have the meaning assigned to such term in Section 6.15.

 

    	I-1

     

    

 

“Broker-Dealer”
shall have the meaning assigned to such term in Section 6.13.

 

“Business
Day” means any Trading Day.

 

“Bylaws”
shall have the meaning assigned to such term in Section 5.3.

 

“Charter”
shall have the meaning assigned to such term in Section 5.3.

 

“Class
B Common Stock” shall have the meaning assigned to such term in Section 3.3.

 

“Closing”
shall have the meaning assigned to such term in Section 2.2.

 

“Closing
Date” means the Execution Date.

 

“Closing
Sale Price” means, for the Common Stock as of any date, the last closing trade price for the Common Stock on the Trading
Market, as reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate the closing
trade price for the Common Stock, then the last traded price for the Common Stock prior to 4:00 p.m., New York City time, as reported
by Bloomberg. All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations
or other similar transactions during such period.

 

“Commencement”
shall have the meaning assigned to such term in Section 7.2.

 

“Commencement
Date” shall have the meaning assigned to such term in Section 7.2.

 

“Commencement
Irrevocable Transfer Agent Instructions” shall have the meaning assigned to such term in Section 10.1(iv).

 

“Commission”
means the U.S. Securities and Exchange Commission or any successor entity.

 

“Commission
Documents” shall mean (1) the Company’s registration statement on Form S-1 (File No. 333-258012) initially filed
with the Commission on July 19, 2021, including any related prospectus or prospectuses, for the registration of the Common Stock to be
issued pursuant to the agreement and plan of merger by the Company, on file with the Commission at the time such registration statement
became effective, including the financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated
therein and all information deemed to be a part thereof as of the effective date of such registration statement under the Securities
Act (the “Company Form S-1 Registration Statement, (2) all reports, schedules, registrations, forms, statements, information and
other documents filed with or furnished to the Commission by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act since June 1, 2021, including, without limitation, the Current Report, (4) each Registration Statement, as the same may be amended
from time to time, the Prospectus contained therein and each Prospectus Supplement thereto, (5) all information contained in such filings
and all documents and disclosures that have been and heretofore shall be incorporated by reference therein, and (6) all other SEC Documents.

 

    	I-2

     

    

 

“Commitment
Period” means the period commencing on the Effective Date of the Initial Registration Statement and expiring on the date
this Agreement is terminated pursuant to Article VIII.

 

“Commitment
Shares” means a number of duly authorized, validly issued, fully paid and non-assessable Shares equal to the quotient obtained
by dividing (i) $750,000 and (ii) the VWAP of the Common Stock on the Commitment Shares Determination Date.

 

“Commitment
Shares Determination Date” means the earlier to occur after the Execution Date of (i) two Trading Days prior to the filing
of the Initial Registration Statement or (ii) the Trading Day prior to date the Investor delivers a written request to the Company for
the Commitment Shares, which date shall be no earlier than the effective date of the Merger.

 

“Common
Stock” shall have the meaning assigned to such term in the recitals of this Agreement.

 

“Common
Stock Equivalents” means any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Compliance
Certificate” shall have the meaning assigned to such term in Section 7.2(ii).

 

“Confidential
Information” means non-public proprietary and confidential information and materials a party, which proprietary and confidential
information and material is not generally known or available to the public or other third parties on a nonconfidential basis.

 

“Contract”
means any written or oral legally binding contract, agreement, understanding, arrangement, subcontract, loan or credit agreement, note,
bond, indenture, mortgage, purchase order, deed of trust, lease, sublease, instrument, or other legally binding commitment, obligation
or undertaking.

 

“Current
Report” shall have the meaning assigned to such term in Section 2.3.

 

“Custodian”
shall mean any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

“Damages”
shall have the meaning assigned to such term in Section 9.1.

 

“DTC”
means The Depository Trust Company, a subsidiary of The Depository Trust & Clearing Corporation, or any successor thereto.

 

“DWAC”
shall have the meaning assigned to such term in Section 5.32.

 

    	I-3

     

    

 

“DWAC
Shares” means shares of Common Stock issued pursuant to this Agreement that are (i) issued in electronic form, (ii) freely
tradable and transferable and without restriction on resale and without stop transfer instructions maintained against the transfer thereof
and (iii) timely credited by the Company to the Investor’s or its designated Broker-Dealer at which the account or accounts to
be credited with the Shares being purchased by Investor are maintained specified DWAC account with DTC under its Fast Automated Securities
Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 

“EDGAR”
means the Commission’s Electronic Data Gathering, Analysis and Retrieval System.

 

“Effective
Date” means, with respect to the Initial Registration Statement filed pursuant to Section 2(a) of the Registration Rights
Agreement (or any post-effective amendment thereto) or any New Registration Statement filed pursuant to Section 2(c) of the Registration
Rights Agreement (or any post-effective amendment thereto), as applicable, the date on which the Initial Registration Statement (or any
post-effective amendment thereto) or any New Registration Statement (or any post-effective amendment thereto) is declared effective by
the Commission.

 

“Eligible
Market” means The Nasdaq Global Market, The Nasdaq Global Select Market, the Nasdaq Capital Market, the New York Stock
Exchange or the NYSE American (or any nationally recognized successor to any of the foregoing).

 

“Encumbrance”
means any security interest, pledge, hypothecation, mortgage, lien or encumbrance, covenant, condition, restriction, easement, charge,
right of first refusal or first offer, or other restriction on title or transfer of any nature whatsoever.

 

“Environmental
Law” means any statute, law, ordinance, regulation, rule or code concerning or relating to: (i) the protection of the environment
or natural resources or, as such relates to exposure to Hazardous Materials, human health and safety (including workplace and industrial
hygiene); (ii) the presence, Release, generation, use, management, handling, transportation, treatment, storage or disposal of Hazardous
Materials; (iii) noise or odor including, without limitation, in the United States, the Comprehensive Environmental Response, Compensation,
and Liability Act, 42 U.S.C. § 9601, et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery
Act of 1976, 42 U.S.C. 6901, et seq.; the Toxic Substances Control Act, 15 U.S.C. 2601, et seq.; the Federal Water Pollution Control
Act, 33 U.S.C. 1251, et seq.; the Hazardous Materials Transportation Act, 49 U.S.C. 5101; the Safe Drinking Water Act, 42 U.S.C. 300f,
et seq.; as it relates to exposure to Hazardous Materials, the Occupational Safety and Health Act, 29 U.S.C. 651, et seq.; the Emergency
Planning and Community Right to Know Act of 1986, 42 U.S.C. 11001, et seq.; the Atomic Energy Act, 42 U.S.C. 2014, et seq.; the Endangered
Species Act, 16 U.S.C. 1531, et seq.; the Federal Insecticide, Fungicide, and Rodenticide Act, 7 U.S.C. 136, et seq.; the Clean Air Act,
42 U.S.C. 7401, et seq.; and the state and local analogues of each of the foregoing federal statutes.

 

“Environmental
Permit” means any Permit, approval, identification number, registration, exemption or license required pursuant to any
applicable Environmental Law.

 

    	I-4

     

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.

 

“Exchange
Cap” shall have the meaning assigned to such term in Section 3.3(a) hereof.

 

“Exempt
Issuance” means the issuance of (a) Common Stock, options or other equity incentive awards to employees, officers, directors
or vendors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by the Company’s Board of Directors
or a majority of the members of a committee of the Board of Directors established for such purpose, (b) (1) any Shares issued to the
Investor pursuant to this Agreement, (2) any securities issued upon the exercise or exchange of or conversion of any shares of Common
Stock or Common Stock Equivalents held by the Investor at any time, or (3) any securities issued upon the exercise or exchange of or
conversion of any Common Stock Equivalents issued and outstanding on the Execution Date, provided that such securities referred to in
this clause (3) have not been amended since the Execution Date to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities, (c) securities issued pursuant to acquisitions, divestitures, licenses,
partnerships, collaborations or strategic transactions approved by the Company’s Board of Directors or a majority of the members
of a committee of directors established for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations or
strategic transactions can have a Variable Rate Transaction component, provided that any such issuance shall only be to a Person (or
to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall
not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities, (d) Common Stock issued by the Company to the Investor or an Affiliate of the Investor in
connection with any “equity line of credit” or other continuous offering or similar offering of Common Stock pursuant to
a written agreement between the Company and the Investor or an Affiliate of the Investor, whereby the Company may sell Common Stock to
the Investor or an Affiliate of the Investor at a future determined price, or (e) Common Stock issued by the Company by any method deemed
to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act.

 

“FINRA”
means the Financial Industry Regulatory Authority.

 

“Floor
Price” means $1.00, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction, the “Floor Price” shall mean the lower of (i) such adjusted price and
(ii) $1.00.

 

    	I-5

     

    

 

“Fundamental
Transaction” means that (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate
or merge with or into (whether or not the Company is the surviving corporation) another Person, with the result that the holders of the
Company’s capital stock immediately prior to such consolidation or merger together beneficially own less than 50% of the outstanding
voting power of the surviving or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of
all or substantially all of the properties or assets of the Company to another Person, or (3) take action to facilitate a purchase, tender
or exchange offer by another Person that is accepted by the holders of more than 50% of the outstanding shares of Common Stock (excluding
any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party
to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination), or (5) reorganize, recapitalize or reclassify its Common Stock, or (ii) any “person”
or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary
voting power represented by issued and outstanding Common Stock; provided, however, that in no event shall the entry by
the Company into the Merger Agreement or the consummation of the transactions contemplated thereby constitute a Fundamental Transaction.

 

“GAAP”
shall have the meaning assigned to such term in Section 5.6(b).

 

“Hazardous
Material” means any substance, material, or other matter regulated as toxic or hazardous, or as a contaminant or for which
standards are imposed, by any governmental authority because of its deleterious impact on the environment including but not limited to
petroleum and petroleum byproduct and distillates, asbestos and asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls,
mold, radon gas, radioactive substances, and poly- and perfluoroalkyl substances.

 

“Initial
Registration Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Intellectual
Property” means all intellectual property and intellectual property rights of every kind and description throughout the
world, including all U.S. and non-U.S.: (a) trademarks, trade dress, service marks, certification marks, logos, slogans, design rights,
names, corporate names, trade names, Internet domain names, URLs, social media accounts and addresses and other similar designations
of source or origin, together with the goodwill symbolized by any of the foregoing (collectively, “Marks”);
(b) patents and patent applications, and any and all related national or international counterparts thereto, including any divisionals,
continuations, continuations-in-part, reissues, reexaminations, substitutions and extensions thereof (collectively, “Patents”);
(c) copyrights and copyrightable subject matter, including databases, data collections (including knowledge databases, customers lists
and customer databases) and rights therein, web site content, rights to compilations, collective works and derivative works, and the
right to create collective and derivative works (collectively, “Copyrights”); (d) rights in Software; (e) rights
under applicable trade secret law and any and all other confidential or proprietary information, know-how, inventions, processes, formulae,
models, and methodologies including research in progress, algorithms, data, databases, data collections, designs, processes, formulae,
drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, source code, source code documentation, beta
testing procedures and beta testing results (collectively, “Trade Secrets”); (f) all applications and registrations,
renewals and extensions for the foregoing; and (g) all rights and remedies against past, present, and future infringement, misappropriation
or other violation thereof.

 

    	I-6

     

    

 

“Investor”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Investor
Party” shall have the meaning assigned to such term in Section 9.1.

 

“IT
Systems and Data” shall have the meaning assigned to such term in Section 5.34.

 

“Knowledge”
means the actual knowledge of the Company’s Chief Executive Officer, the Company’s President, and the Company’s Chief
Financial Officer, in each case after reasonable inquiry of all officers and directors of the Company and its Subsidiaries who would
reasonably be expected to have knowledge or information with respect to the matter in question.

 

“Material
Adverse Effect” means (i) any condition, occurrence, state of facts or event having, or insofar as reasonably can be foreseen
would likely have, any material adverse effect on the legality, validity or enforceability of the Transaction Documents or the transactions
contemplated thereby, (ii) any condition, occurrence, state of facts or event having, or insofar as reasonably can be foreseen would
likely have, any effect on the business, operations, properties or financial condition of the Company that is material and adverse to
the Company and its Subsidiaries, taken as a whole, and/or (iii) any condition, occurrence, state of facts or event that would, or insofar
as reasonably can be foreseen would likely, prohibit or otherwise materially interfere with or delay the ability of the Company to perform
any of its obligations under any of the Transaction Documents to which it is a party; provided, however, that with respect to clause
(ii), in no event would any of the following (or the effect of any of the following), alone or in combination, be deemed to constitute,
or be taken into account in determining whether there has been or will be, a “Material Adverse Effect” (except
in the case of clause (a), (b), (d) and (f), in each case, to the extent that such event, change, circumstance or development disproportionately
affects the Company and its Subsidiaries, taken as a whole, as compared to other Persons operating in any of the industries in which
the Company or any of its Subsidiaries operates): (a) any change or development after the Execution Date in applicable laws or GAAP or
any official interpretation thereof, (b) any change or development after the Execution Date in interest rates or economic, political,
legislative, regulatory, financial, commodity, currency, electricity or natural gas conditions or other market conditions generally affecting
any of the foregoing, the economy or the industry in which the Company or any of its Subsidiaries operates, (c) the announcement or the
execution of this Agreement and the Registration Rights Agreement, or the performance of the Company’s obligations under the Transaction
Documents, including the impact thereof on relationships, contractual or otherwise, with customers, suppliers, licensors, distributors,
regulatory agencies, partners, providers and employees (provided that the exceptions in this clause (c) shall not be deemed to apply
to references to “Material Adverse Effect” in the representations and warranties set forth in Section 5.5 and, to the extent
related thereto, the conditions in Section 7.1(ii) and Section 7.2(i)), (d) any change or development generally affecting
any of the industries or markets in which the Company or any of its Subsidiaries operates, (e) any earthquake, hurricane, tsunami, tornado,
flood, mudslide, wildfire or other natural disaster, epidemic, disease outbreak, pandemic (including the COVID-19 or SARS-CoV-2 virus
(or any mutation or variation thereof or related health condition)), weather condition, explosion, fire, act of God or other force majeure
event (other than any such event resulting in material destruction or permanent damage to the Company powerplant and/or a material portion
of the equipment located therein, all of which may be taken into account for purposes of determining whether a Material Adverse Effect
has occurred or is reasonably likely to occur), or (f) any national or international political or social conditions in countries in which,
or in the proximate geographic region of which, the Company operates, including the engagement by the United States or such other countries
in hostilities or the escalation thereof, whether or not pursuant to the declaration of a national emergency or war, or the occurrence
or the escalation of any military or terrorist attack (including any internet or “cyber” attack or hacking) upon the United
States or such other country, or any territories, possessions, or diplomatic or consular offices of the United States or such other countries
or upon any United States or such other country military installation, equipment or personnel.

 

    	I-7

     

    

 

“Material
Contracts” means any other Contract that is expressly referred to in or filed or incorporated by reference as an exhibit
to a Commission Document or that, individually or in the aggregate, if terminated or subject to default by a party thereto, would have
or would reasonably be expected to have a Material Adverse Effect.

 

“Merger”
means the merger of AHAC Merger Sub Inc. with and into Ocean Biomedical, Inc. pursuant to the Merger Agreement.

 

“Merger
Agreement” means that certain Agreement and Plan of Merger by and among the Company, AHAC Merger Sub Inc., Aesther Healthcare
Sponsor, LLC, and Ocean Biomedical, Inc.

 

“Minimum
Price” means the average closing price of the Common Stock on the Trading Market (as reflected on Nasdaq.com) for the five
(5) consecutive Trading Days ending on and including the Effective Date (subject to adjustment for any reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction that occurs on or after the date of this Agreement).

 

“New
Registration Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Notice
of Effectiveness” shall have the meaning assigned to such term in Section 10.1(iii).

 

“Opening
Sale Price” means, for the Common Stock as of any date, the first opening trade price for the Common Stock on the Trading
Market, as reported by Bloomberg.

 

“PEA
Period” means the period commencing at 9:30 a.m., New York City time, on the fifth (5th) Trading Day immediately prior
to the filing of any post-effective amendment to the Initial Registration Statement or any New Registration Statement, and ending at
9:30 a.m., New York City time, on the Trading Day immediately following, the Effective Date of such post-effective amendment.

 

    	I-8

     

    

 

“Permitted
Encumbrances” means (a) liens for taxes not yet due or delinquent or the validity or amount of which is being contested
in good faith by appropriate proceedings and for which adequate accruals or reserves have been established in accordance with GAAP on
the applicable financial statements; (b) mechanics’, materialmens’, carriers’, workers’, repairers’ and
other similar Encumbrances or security obligations incurred in the ordinary course of business and arising by operation of law or the
validity or amount of which is being contested in good faith by appropriate proceedings; (c) pledges, deposits or other Encumbrances
securing the performance of bids, trade Contracts, leases or statutory obligations (including workers’ compensation, unemployment
insurance or other social security legislation); (d) Encumbrances and other imperfections of title that do not materially impair the
use or occupancy of the property to which they relate in the conduct of the business of the Company and its Subsidiaries as currently
conducted; (e) Encumbrances arising under conditional sales Contracts and equipment leases with third parties and other Encumbrances
arising on assets and products sold in the ordinary course of business consistent with past practice and non-exclusive licenses of Intellectual
Property entered into in the ordinary course of business consistent with past practice; (f) landlords’ liens and Encumbrances on
leases, subleases, easements, licenses, rights of use, rights to access and rights of way arising therefrom or benefiting or created
by any superior estate, right or interest; (g) any zoning, entitlement, conservation restriction and other land use and environmental
regulations by governmental authorities; (h) all covenants, conditions, restrictions, easements, charges, rights-of-way and other similar
matters of record or that would be disclosed by an accurate survey or inspection of the real property, in each case that do not materially
impair the use or occupancy of the property to which they relate in the conduct of the business of the Company and its Subsidiaries as
currently conducted; (i) Encumbrances identified in the financial statements included or incorporated by reference in the Commission
Documents; (j) Encumbrances created or incurred under the equipment financing arrangements or equipment loans; and (k) Encumbrances on
equity or debt securities resulting from applicable securities laws.

 

“Permits”
shall have the meaning assigned to such term in Section 5.17(a).

 

“Person”
means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company,
trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.

 

“Principal
Market” shall mean any of the national exchanges (i.e. NYSE, AMEX, Nasdaq), or principal quotation systems (i.e. OTCQX,
OTCQB, OTC Pink, the OTC Bulletin Board), or other principal exchange or recognized quotation system which is at the time the principal
trading platform or market for the Common Stock.

 

“Prospectus”
means the prospectus in the form included in a Registration Statement, as supplemented from time to time by any Prospectus Supplement,
including the documents incorporated by reference therein.

 

“Prospectus
Supplement” means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule
424(b) under the Securities Act, including the documents incorporated by reference therein.

 

“Purchase”
shall have the meaning assigned to such term in Section 3.1.

 

“Purchase
Amount” shall have the meaning assigned to such term in Section 3.2.

 

“Purchase
Condition Satisfaction Time” shall have the meaning assigned to such term in Section 7.3.

 

    	I-9

     

    

 

“Purchase
Commencement Time” means, with respect to a Purchase made pursuant to Section 3.1, 9:30:01 a.m., New York City time,
on the applicable Purchase Notice Date.

 

“Purchase
Notice” means, with respect to a Purchase made pursuant to Section 3.1, an irrevocable written notice, substantially
in the form Exhibit D hereto, delivered by the Company to the Investor directing the Investor to purchase Purchase Notice Shares (such
specified Purchase Notice Shares subject to adjustment as set forth in Section 3.1 as necessary to give effect to the Purchase
Notice Limit), at the applicable Purchase Price therefor on the applicable Purchase Settlement Date for such Purchase in accordance with
this Agreement.

 

“Purchase
Notice Date” means, with respect to a Purchase made pursuant to Section 3.1, (i) the Trading Day that the applicable
Purchase Notice is received by email by the Investor if such notice is received on or prior to 9:00 a.m. New York time or (ii) the next
Trading Day if it is received by email after 9:00 a.m. New York time on a Trading Day or at any time on a day which is not a Trading
Day.

 

“Purchase
Notice Limit” means, with respect to a Purchase made pursuant to Section 3.1, a number of shares of Common Stock
equal to the lesser of (i) a number of shares of Common Stock which, when aggregated with all other shares of Common Stock then beneficially
owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder),
would result in the beneficial ownership by the Investor of more than the Beneficial Ownership Limitation, (ii) a number of shares of
Common Stock equal to the Average Daily Trading Volume multiplied by 67%, and (iii) a number of shares of Common Stock equal to quotient
obtained by dividing $2,000,000 and the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the Purchase
Notice Date.

 

“Purchase
Notice Shares” means, with respect to a Purchase made pursuant to Section 3.1, the number of Shares to be purchased
by the Investor in such Purchase as specified by the Company in the applicable Purchase Notice, which number of Shares shall not exceed
the applicable Purchase Notice Limit, subject to adjustment provided herein. In the event that the price of the Common Stock during the
Valuation Period trades at or below the Threshold Price, the number of Purchase Notice Shares for the applicable Purchase Notice shall
be adjusted to the Adjusted Purchase Notice Share Amount, and the issuance of any and all Purchase Notice Shares in excess of the Adjusted
Purchase Notice Share Amount shall be void ab initio.

 

“Purchase
Price” shall equal to ninety-three percent (93.0%) multiplied by the lowest daily VWAP over the applicable Valuation Period;
provided, however, that if the Adjusted Purchase Notice Share Amount is used, the Purchase Price shall be the Threshold Purchase Price.

 

“Purchase
Settlement Date” shall have the meaning assigned to such term in Section 3.1.

 

“Registrable
Securities” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Registration
Rights Agreement” shall have the meaning assigned to such term in the recitals hereof.

 

    	I-10

     

    

 

“Registration
Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Regulation
D” shall have the meaning assigned to such term in the recitals of this Agreement.

 

“Release”
means disposing, discharging, injecting, spilling, leaking, pumping, pouring, leaching, dumping, emitting, escaping or emptying into
or upon, from, or migrating through of Hazardous Materials, within or into, the air or any soil, sediment, subsurface strata, surface
water or groundwater, natural resources or structure.

 

“Remedial
Action” means any action required to investigate, clean up, remove or remediate, or conduct remedial, responsive, monitoring
or corrective actions with respect to, any presence or Release of Hazardous Materials.

 

“Restricted
Period” shall have the meaning assigned to such term in Section 6.9(i).

 

“Restricted
Person” shall have the meaning assigned to such term in Section 6.9(i).

 

“Restricted
Persons” shall have the meaning assigned to such term in Section 6.9(i).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect.

 

“Sanctions”
shall have the meaning assigned to such term in Section 5.33.

 

“Section
4(a)(2)” shall have the meaning assigned to such term in the recitals of this Agreement.

 

“Securities
Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.

 

“Shares”
shall mean the shares of Common Stock that are and/or may be purchased by the Investor under this Agreement pursuant to one or more Purchase
Notices.

 

“Short
Sales” shall mean “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange
Act.

 

“Software”
means any computer programs (whether in source code, object code or other form, and including software-as-a-service), algorithms, databases,
compilations and data technology supporting the foregoing, and all documentation, including user manuals and training materials, related
to any of the foregoing.

 

“Subsidiary”
shall mean any corporation or other entity, other than Support.com, Inc., of which at least a majority of the securities or other ownership
interest having ordinary voting power for the election of directors or other persons performing similar functions are at the time owned
directly or indirectly by the Company and/or any of its other Subsidiaries.

 

    	I-11

     

    

 

“Threshold
Price” shall equal to 90% of the Opening Sale Price on the Purchase Notice Date.

 

“Threshold
Purchase Price” means the Threshold Price multiplied by 95%.

 

“Total
Commitment” shall have the meaning assigned to such term in Section 2.1.

 

“Trading
Day” shall mean any day on which the Trading Market or, if the Common Stock is then listed on an Eligible Market, such
Eligible Market is open for trading (regular way), including any day on which the Trading Market (or such Eligible Market, as applicable)
is open for trading (regular way) for a period of time less than the customary time.

 

“Trading
Market” means The Nasdaq Global Select Market (or any nationally recognized successor thereto).

 

“Transaction
Documents” means, collectively, this Agreement (as qualified by the Commission Documents) and the exhibits hereto, the
Registration Rights Agreement and the exhibits thereto, and each of the other agreements, documents, certificates and instruments entered
into or furnished by the parties hereto in connection with the transactions contemplated hereby and thereby.

 

“Transfer
Agent” means Continental Stock Transfer & Trust Company, or any successor transfer agent of the Company.

 

“Valuation
Period” shall mean the two (2) consecutive Trading Days commencing on and including the Purchase Notice Date. For avoidance
of doubt, the Purchase Notice Date shall be the first Trading Day in the Valuation Period.

 

“Variable
Rate Transaction” means a transaction in which the Company (i) issues or sells any equity or debt securities that are convertible
into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock or Common Stock Equivalents
either (A) at a conversion price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices
of or quotations for the Common Stock at any time after the initial issuance of such equity or debt securities, or (B) with a conversion,
exercise or exchange price that is subject to being reset at some future date after the initial issuance of such equity or debt security
or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market
for the Common Stock (including, without limitation, any “full ratchet” or “weighted average” anti-dilution provisions,
but not including any standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other
similar transaction), (ii) issues or sells any equity or debt securities, including without limitation, Common Stock or Common Stock
Equivalents, either (A) at a price that is subject to being reset at some future date after the initial issuance of such debt or equity
security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the
market for the Common Stock (other than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction), or (B) that are subject to or contain any put, call, redemption, buy-back, price-reset or
other similar provision or mechanism (including, without limitation, a “Black-Scholes” put or call right, other than in connection
with a Fundamental Transaction) that provides for the issuance of additional equity securities of the Company or the payment of cash
by the Company, or (iii) enters into any agreement, including, but not limited to, an “equity line of credit” or “at
the market offering” or other continuous offering or similar offering of Common Stock or Common Stock Equivalents, whereby the
Company may sell Common Stock or Common Stock Equivalents at a future determined price.

 

“VWAP”
means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market (or, if the
Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities market
on which such security is then traded), during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time,
as reported by Bloomberg through its “VAP” function (set to 09:30 start time and 16:00 end time) or, if the foregoing does
not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board
for such security during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time, as reported by Bloomberg,
or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets”
by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security on such date on any of the foregoing
bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Investor.
If the Company and the Investor are unable to agree upon the fair market value of such security, then such dispute shall be resolved
in accordance with the procedures in Section 10.16. All such determinations shall be appropriately adjusted for any share dividend,
share split, share combination, recapitalization or other similar transaction during such period.

 

    	I-12

     

    

 

EXHIBIT
A TO THE

COMMON STOCK PURCHASE AGREEMENT

[TO
BE FURNISHED SEPARATELY]

 

    	 

     

    

 

 

EXHIBIT
B TO THE

COMMON STOCK PURCHASE AGREEMENT

CERTIFICATE OF THE COMPANY

 

CLOSING
CERTIFICATE

 

[•],
2022

 

The
undersigned, the [•] of Aesther Healthcare Acquisition Corporation, a Delaware corporation (the “Company”),
delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of September 7, 2022 (the “Agreement”),
by and between the Company and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”),
and hereby certifies on the Execution Date that (capitalized terms used herein without definition have the meanings assigned to them
in the Agreement):

 

1.
Attached hereto as Exhibit A is a true, complete and correct copy of the Amended and Restated Certificate of Incorporation of the Company,
as amended through the date hereof, as filed with the Secretary of State of the State of Delaware (the “Certificate of Incorporation”).
The Certificate of Incorporation of the Company has not been further amended or restated, and no document with respect to any amendment
to the Certificate of Incorporation of the Company has been filed in the office of the Secretary of State of the State of Delaware since
the date shown on the face of the state certification relating to the Certificate of Incorporation, which is in full force and effect
on the date hereof, and no action has been taken by the Company in contemplation of any such amendment or the dissolution, merger or
consolidation of the Company.

 

2.
Attached hereto as Exhibit B is a true and complete copy of the Amended and Restated Bylaws of the Company, as amended and restated through,
and as in full force and effect on, the date hereof (the “Bylaws”), and no proposal for any amendment, repeal
or other modification to the Bylaws of the Company has been taken or is currently pending before the Board of Directors or stockholders
of the Company.

 

3.
The Board of Directors of the Company has approved the transactions contemplated by the Transaction Documents; said approval has not
been amended, rescinded or modified and remains in full force and effect as of the date hereof. Attached hereto as Exhibit C are true,
correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company via unanimous written consent on
[•], 2022.

 

4.
Each person who, as an officer of the Company, or as attorney-in-fact of an officer of the Company, signed the Transaction Documents
to which the Company is a party, was duly elected, qualified and acting as such officer or duly appointed and acting as such attorney-in-fact,
and the signature of each such person appearing on any such document is his genuine signature.

 

IN
WITNESS WHEREOF, I have signed my name as of the date first above written.

 

	 	 	 
	 	Name:	 
	 	Title:	 

 

    	 

     

    

 

EXHIBIT
C TO THE

COMMON
STOCK PURCHASE AGREEMENT

COMPLIANCE
CERTIFICATE

 

The
undersigned, the [•] of Aesther Healthcare Acquisition Corporation, a Delaware corporation (the “Company”),
delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of September 7, 2022 (the “Agreement”),
by and between the Company and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”),
and hereby certifies on the date hereof that, to the best of his knowledge after reasonable investigation, on behalf of the Company (capitalized
terms used herein without definition have the meanings assigned to them in the Agreement):

 

1.
The undersigned is the duly appointed [•] of the Company.

 

2.
Except as set forth in the Commission Documents, the representations and warranties of the Company set forth in Article V of the
Agreement (i) that are not qualified by “materiality” or “Material Adverse Effect” are true and correct in all
material respects as of [the Commencement Date] [the date hereof] with the same force and effect as if made on [the Commencement Date]
[the date hereof], except to the extent such representations and warranties are as of another date, in which case, such representations
and warranties are true and correct in all material respects as of such other date and (ii) that are qualified by “materiality”
or “Material Adverse Effect” are true and correct as of [the Commencement Date] [the date hereof] with the same force and
effect as if made on [the Commencement Date] [the date hereof], except to the extent such representations and warranties are as of another
date, in which case, such representations and warranties are true and correct as of such other date, and except, in the cases of clause
(i) and clause (ii), for any failures that have been disclosed in accordance with Section Section 7.2(i) of the Agreement.

 

3.
The Company has performed, satisfied and complied in all material respects with all covenants, agreements and conditions precedent required
by the Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by the Company [at or prior to Commencement][on
or prior to the date hereof]. The conditions set forth in Section 7.2 of the Agreement have been satisfied.

 

4.
The Shares issuable in respect of each Purchase Notice effected pursuant to the Agreement shall be delivered to the Investor electronically
as DWAC Shares, and shall be freely tradable and transferable and without restriction on resale and without any stop transfer instructions
maintained against such Shares.

 

5.
As of [the Commencement Date][the date hereof], the Company does not possess any material non-public information.

 

6.
As of [the Commencement Date][the date hereof], the Company has reserved out of its authorized and unissued Common Stock [•] shares
of Common Stock solely for the purpose of effecting Purchases under the Agreement.

 

7.
No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus under the Securities Act has been
issued and no proceedings for such purpose or pursuant to Section 8A of the Securities Act are pending before or, to the knowledge of
the Company, threatened by the Commission.

 

The
undersigned has executed this Certificate this [•] day of [•], 2022.

 

	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 

 

    	 

     

    

 

EXHIBIT
D

FORM
OF PURCHASE NOTICE

TO:
WHITE LION CAPITAL LLC

 

We
refer to the Common Stock Purchase Agreement, dated as of September 7, 2022 (the “Agreement”), entered into
by and between Aesther Healthcare Acquisition Corporation and White Lion Capital LLC. Capitalized terms defined in the Agreement shall,
unless otherwise defined herein, have the same meaning when used herein.

 

We
hereby:

 

1)
Give you notice that we require you to purchase __________ Purchase Notice Shares pursuant to the Agreement.

 

2)
Certify that, as of the date hereof, the conditions set forth in Section 7.2 and Section 7.3 of the Agreement are satisfied.

 

	 	AESTHER HEALTHCARE ACQUISITION CORPORATION
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]